Artykuły w czasopismach: „616.9 23”

1

Fung, Isaac Chun-Hai, Elizabeth B. Blankenship, M. Elizabeth Goff, Lindsay A. Mullican, Kwun Cheung Chan, Nitin Saroha, Carmen H. Duke, Marina E. Eremeeva, King-Wa Fu i Zion Tsz Ho Tse. "Zika-Virus-Related Photo Sharing on Pinterest and Instagram". Disaster Medicine and Public Health Preparedness 11, nr 6 (23.03.2017): 656–59. http://dx.doi.org/10.1017/dmp.2017.23.

Pełny tekst źródła

Streszczenie:

AbstractObjectivePinterest (San Francisco, CA) and Instagram (Menlo Park, CA) are 2 popular photo-sharing social media platforms among young individuals. We assessed differences between Instagram and Pinterest in relaying photographic information regarding Zika virus. Specifically, we investigated whether the percentage of Zika-virus-related photos with Spanish or Portuguese texts embedded therein was higher for Instagram than for Pinterest and whether the contents of Zika-virus-related photos shared on Pinterest were different from those shared on Instagram.MethodsWe retrieved and manually coded 616 Pinterest (key words: “zika” AND “virus”) and 616 Instagram (hashtag: #zikavirus) photos.ResultsAmong the manually coded samples, 47% (290/616) of Pinterest photos and 23% (144/616) of Instagram photos were relevant to Zika virus. Words were embedded in 57% (164/290) of relevant Pinterest photos and all 144 relevant Instagram photos. Among the photos with embedded words, photos in Spanish or Portuguese were more prevalent on Instagram (77/144, 53%) than on Pinterest (14/164, 9%). There were more Zika-virus-related photos on Instagram than on Pinterest pertinent to Zika virus prevention (59/144, 41%, versus 41/290, 14%; P<0.0001), the effects of Zika virus on pregnancy (27/144, 19%, versus 32/290, 11%; P=0.04), and Zika-virus-associated deaths (4/144, 2%, versus 0/290, 0%; P=0.01).ConclusionsPinterest and Instagram are similar platforms for Zika virus prevention communication. (Disaster Med Public Health Preparedness. 2017;11:656–659)

Style APA, Harvard, Vancouver, ISO itp.

2

Minasyan, Elya, Clodet Stepanians, Gevorg Tamamyan i Lala Vagharshakyan. "ALL-616 Analysis of PEG-Asparaginase Associated Adverse Events in the Treatment of Pediatric Acute Lymphoblastic Leukemia". Clinical Lymphoma Myeloma and Leukemia 23 (wrzesień 2023): S256—S257. http://dx.doi.org/10.1016/s2152-2650(23)00970-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

3

Rahayu, Risma Ratri, i Ula Nisa El Fauziah. "SPEECH ACTS OF U.K. PRIME MINISTER BORISH JOHNSON’S SPEECH". PROJECT (Professional Journal of English Education) 4, nr 4 (12.07.2021): 609. http://dx.doi.org/10.22460/project.v4i4.p609-616.

Pełny tekst źródła

Streszczenie:

Abstract This research was to investigate speech acts of Borish Jonshon’s speech concern in the illocutionary act and the use of speech act analysis by Hymes (2014). The speech was held in Prime Minister’s office and Borish Johnson has used a national TV address at 8.30 p.m. The data of this research taken from the script and speech video of the U.K. Prime Minister named Borish Johnson on 23 March 2020 which talked about Covid-19. The research applied descriptive qualitative as a method and hold in Yule’s speech act theory. Based on the analysis, the researcher was found and analyze 222 utterances. Those are consist of, 36% representative, 33% declarative, 16% directive, 9% expressive, and 6% commissive. As the result was representative is the highest use of the illocutionary aspect found in this research. It can be seen that Borish Johnson hoped that his audiences would follow what he said to reduce the coronavirus disease - 19. Keywords: Pragmatics, Speech Act, Covid-19

Style APA, Harvard, Vancouver, ISO itp.

4

Selvaraj, Kavitha, Alicia Olave-Pichon, Irwin Benuck, Adolfo J. Ariza i Helen J. Binns. "Characteristics of Children Referred to a Lipid Clinic Before and After the Universal Screening Guidelines". Clinical Pediatrics 58, nr 6 (10.03.2019): 656–64. http://dx.doi.org/10.1177/0009922819834282.

Pełny tekst źródła

Streszczenie:

In 2011, universal lipid screening was recommended for children aged 9 to 11 years; the impact of this recommendation on the lipid clinic setting is unknown. We examined the rate of primary and secondary dyslipidemia diagnoses in a lipid clinic before (2010-2011) and after (2012-2015) the guideline recommendation. We conducted a retrospective study of new clinic patients aged 0 to 20 years seen between April 2010 and April 2015. Chi-square testing was applied. The 345 subjects were 58% males; 48% ≥13 years; 56% Hispanic; and 59% obese. There was no difference in the rate of dyslipidemia diagnoses between periods (before: primary 23%, secondary 73%, no dyslipidemia 4% vs after: 22%, 72%, 6%, respectively; P = .616). There was no significant difference between periods in subject demographics for the total sample, but among those with primary dyslipidemia, pre- to post-guideline percentage of subjects with public insurance decreased (71% to 39%; P = .006). Additional strategies to increase identification of children with dyslipidemia are needed.

Style APA, Harvard, Vancouver, ISO itp.

5

Palomino, Guadalupe, Javier Martínez-Ramón, Verónica Cepeda-Cornejo, Miriam Ladd-Otero, Patricia Romero i Jerónimo Reyes-Santiago. "Chromosome Number, Ploidy Level, and Nuclear DNA Content in 23 Species of Echeveria (Crassulaceae)". Genes 12, nr 12 (3.12.2021): 1950. http://dx.doi.org/10.3390/genes12121950.

Pełny tekst źródła

Streszczenie:

Echeveria is a polyploid genus with a wide diversity of species and morphologies. The number of species registered for Echeveria is approximately 170; many of them are native to Mexico. This genus is of special interest in cytogenetic research because it has a variety of chromosome numbers and ploidy levels. Additionally, there are no studies concerning nuclear DNA content and the extent of endopolyploidy. This work aims to investigate the cytogenetic characteristics of 23 species of Echeveria collected in 9 states of Mexico, analyzing 2n chromosome numbers, ploidy level, nuclear DNA content, and endopolyploidy levels. Chromosome numbers were obtained from root tips. DNA content was obtained from the leaf parenchyma, which was processed according to the two-step protocol with Otto solutions and propidium iodide as fluorochrome, and then analyzed by flow cytometry. From the 23 species of Echeveria analyzed, 16 species lacked previous reports of 2n chromosome numbers. The 2n chromosome numbers found and analyzed in this research for Echeveria species ranged from 24 to 270. The range of 2C nuclear DNA amounts ranged from 1.26 pg in E. catorce to 7.70 pg in E. roseiflora, while the 1C values were 616 Mbp and 753 Mbp, respectively, for the same species. However, differences in the level of endopolyploidy nuclei were found, corresponding to 4 endocycles (8C, 16C, 32C and 64C) in E. olivacea, E. catorce, E. juarezensis and E. perezcalixii. In contrast, E. longiflora presented 3 endocycles (8C, 16C and 32C) and E. roseiflora presented 2 endocycles (8C and 16C). It has been suggested that polyploidization and diploidization processes, together with the presence of endopolyploidy, allowed Echeveria species to adapt and colonize new adverse environments.

Style APA, Harvard, Vancouver, ISO itp.

6

Rektiansyah, Rahmat Robbi, i Ilmiawan Auwalin. "Analisis Dampak Kesadaran Halal dan Label Halal terhadap Niat Beli Mie Instan Korea Pada Remaja di Sumenep Melalui Sikap". Jurnal Ekonomi Syariah Teori dan Terapan 9, nr 5 (30.09.2022): 600–616. http://dx.doi.org/10.20473/vol9iss20225pp600-616.

Pełny tekst źródła

Streszczenie:

ABSTRAK Tujuan dilangsungkannya sebuah penelitian ini ialah untuk mengkaji pengaruh kesadaran halal dan label halal terhadap niat beli mie instan Korea pada remaja di Sumenep melalui sikap. Metode penelitian yang digunakan yaitu kuantitatif dengan menggunakan data primer. Sampel yang digunakan yaitu 100 responden yang belum pernah membeli mie instan Korea. Pengujian menggunakan analisis SEM-PLS dengan konstruk yang menunjukkan semua konstruk mempunyai hasil yang valid, sehingga dilanjutkan pengujian pada hubungan antar variabelnya. Secara langsung kesadaran halal berpengaruh signifikan terhadap sikap, namun kesadaran halal tidak berpengaruh signifikan terhadap niat beli. Label halal berpengaruh secara signifikan t atas niat beli, namun label halal tidak berpengaruh signifikan terhadap sikap, dan sikap berpengaruh secara signifikan atas niat beli. Secara tidak langsung, kesadaran halal berpengaruh signifikan terhadap niat beli jika melalui sikap, sedangkan label halal tidak berpengaruh signifikan terhadap niat beli jika melalui sikap. Penelitian ini hanya berfokus terhadap remaja generasi Z usia 13-23 tahun di Sumenep yang belum pernah membeli mie instan Korea. Adapun saran pada penelitian ini adalah remaja generasi Z di Sumenep diharapkan lebih memperhatikan dan peduli terhadap kehalalan suatu produk yang dikonsumsi, dan bagi peneliti selanjutnya diharapkan meneliti hal serupa dengan mengganti objek dan tempat penelitian. Kata Kunci: Kesadaran Halal, Label Halal, Niat Beli, Sikap. ABSTRACT The purpose of this research is to examine the effect of halal awareness and halal label on the intention to buy Korean instant noodles in adolescents in Sumenep through attitudes. The research method used is quantitative using primary data. The sample used is 100 respondents who have never bought Korean instant noodles. The test uses SEM-PLS analysis with constructs that show all constructs have valid results, so that testing continues on the relationship between the variables. Halal awareness directly has a significant effect on attitudes, but halal awareness has no significant effect on purchase intention. Halal labels have a significant effect on purchase intention, but halal labels have no significant effect on attitudes, and attitudes have a significant effect on purchase intentions. Indirectly, halal awareness has a significant effect on purchase intention if it is through attitude, while the halal label has no significant effect on purchase intention if it is through attitude. This study only focuses on Generation Z teenagers aged 13-23 years in Sumenep who have never bought Korean instant noodles. The suggestion in this study is that Generation Z teenagers in Sumenep are expected to pay more attention and care about the halalness of a product that is consumed, and for future researchers it is expected to examine similar things by changing the object and place of research. Keywords: Halal Awareness, Halal Labels, Purchase Intention. Attitudes. DAFTAR PUSTAKA Abd Rahman, A., Asrarhaghighi, E., & Ab Rahman, S. (2015). Consumers and halal cosmetic products: Knowledge, religiosity, attitude and intention. Journal of Islamic Marketing, 6(1), 148–163. https://doi.org/10.1108/JIMA-09-2013-0068 Adisumarto, H. (2000). Hukum perusahaan mengenai hak atas kepemilikan intelektual (Hak cipta, hak paten, hak merek). Bandung: Mandar Magu. Adiwarman, K. (2010). Ekonomi mikro Islam. Jakarta: PT. RajaGrafindo Persada. Ahaari, J. A. N., & Arifin, N. S. M. (2010). Dimension halal purchase intention: A preliminary study. International Review of Business Research Papers, 6 (4), 444–456. Aliman, N.K. dan Othman, M. N. (2007). Purchasing local and foreign brands: What product attributes matter? 13th astutiAsia Pacific Management Conference, Melbourne, Australia, 400–411. Ambali, A. R., & Bakar, A. N. (2014). People’s awareness on halal foods and products: Potential issues for policy-makers. Procedia - Social and Behavioral Sciences, 121(September 2012), 3–25. https://doi.org/10.1016/j.sbspro.2014.01.1104 Astuti, Y., & Asih, D. (2021). Country of origin, religiosity and halal awareness: A case study of purchase intention of Korean food. Journal of Asian Finance, Economics and Business, 8(4), 0413–0421. https://doi.org/10.13106/jafeb.2021.vol8.no4.0413 Awan, H. M., Siddiquei, A. N., & Haider, Z. (2015). Factors affecting Halal purchase intention – evidence from Pakistan’s halal food sector. Management Research Review, 38(6), 640–660. https://doi.org/10.1108/mrr-01-2014-0022 Azam, A. (2016). An empirical study on non-Muslim’s packaged halal food manufacturers . Journal of Islamic Marketing, 7(4), 441–460. https://doi.org/10.1108/jima-12-2014-0084 Aziz, Y. A., & Chok, N. V. (2013). The role of halal awareness, halal certification, and marketing components in determining halal purchase intention among non-Muslims in Malaysia: A Structural equation modeling approach. Journal of International Food and Agribusiness Marketing, 25(1), 1–23. https://doi.org/10.1080/08974438.2013.723997 Aziz, Y. A., Vui, C. N., Yuhanis, A. A., & Chok, N. V. (2012). The role of halal awareness and halal certification in influencing non-Muslims’ purchase intention. In Proceedings of the 3rd International Conference on Business and Economic Research (3rd ICBER 2012), March, 1819–1830. BPS. (2021). Hasil sensus penduduk 2020 jumlah penduduk Kabupaten Sumenep (Issue 01). Briliana, V., & Mursito, N. (2017). Exploring antecedents and consequences of Indonesian Muslim youths’ attitude towards halal cosmetic products: A case study in Jakarta. Asia Pacific Management Review, 22(4), 176–184. https://doi.org/10.1016/j.apmrv.2017.07.012 Garg, P., & Joshi, R. (2018). Purchase intention of “Halal” brands in India: the mediating effect of attitude. Journal of Islamic Marketing, 9(3), 683–694. https://doi.org/10.1108/JIMA-11-2017-0125 Hair, J., Black, W., Babin, B., & Anderson, R. (2010). Multivariate data analysis: A global perspective. Pearson Education Hasan, H. (2016). A study on awareness and perception towards halal foods among Muslim students in Kota Kinabalu, Sabah. Australia-Middle East Conference on Business and Social Sciences, 803–804. Hendradewi, S., Mustika, A., & Darsiah, A. (2021). Pengaruh kesadaran halal dan label halal terhadap minat beli mie instan Korea pada remaja sekolah di Jakarta. Jurnal Ilmiah Pariwisata, 26(2), 204–212. https://doi.org/10.30647/jip.v26i2.1510 Izzuddin, A. (2018). Pengaruh label halal, kesadaran halal, dan bahan makanan terhadap minat beli makanan kuliner. Jurnal Penelitian Ipteks, 3(2), 100–114. https://doi.org/10.32528/ipteks.v3i2.1886 Kotler, P. (2008). Manajemen pemasaran (Edisi terjemahan). Erlangga: Jakarta. Mukhtar, A., & Butt, M. M. (2012). Intention to choose Halal products: The role of religiosity. Journal of Islamic Marketing, 3(2), 108–120. https://doi.org/10.1108/17590831211232519 Nisrina, D., Widodo, I. A., Larassari, I. B., Rahmaji, F., Kinanthi, G., & Adi, H. (2020). Studi tentang pengaruh budaya Korea pada penggemar K-Pop. Jurnal Penelitian Humaniora, 21(1), 78–88. Rambe, Y., & Afifuddin, S. (2012). Pengaruh pencantuman label halal pada kemasan mie instan terhadap minat pembelian masyarakat Muslim (Studi kasus pada mahasiswa Universitas Al-washliyah, Medan). Jurnal Ekonomi dan Keuangan, 1(1), 14866. Rangkuti. (2010). Pengaruh labelisasi halal terhadap keputusan pembelian produk makanan dalam kemasan (Snack merek Chitato) pada mahasiswa fakultas hukum Universitas Muhammadiyah Sumatera Utara). Skripsi tidak dipublikasikan. Medan: Universitas Sumatera Utara. Rochmanto, B. Al. (2014). Pengaruh pengetahuan produk dan norma religius tehadap sikap konsumen dalam niat mengkonsumsi produk makanan dan minuman halal. Diponegoro Journal of Management, 4(1), 280-291. Sarwono, S. ., & Meinarno, E. . (2009). Psikologi remaja. Surabaya: Raja Grafindo Persada. Schiffman, L. G., & Wisenblit, J. (2019). Consumer behavior. Harlow, United Kingdom: Pearson Education Limited. Setiawati, L. M., Chairy, C., & Syahrivar, J. (2019). Factors affecting the intention to buy halal food by the millennial generation: The mediating role of attitude. DeReMa (Development Research of Management): Jurnal Manajemen, 14(2), 175. https://doi.org/10.19166/derema.v14i2.1738 Shafie, S., & Othman, M. N. (2008). Halal certification: An international marketing issues and challenges. http://www.ncbi.nlm.nih.gov/pubmed/12568103 Shim, D. (2006). Hybridity and the rise of Korean popular culture in Asia. Media, Culture and Society, 28(1), 25–44. https://doi.org/10.1177/0163443706059278 Sudarsono, H., & Nugrohowati, R. N. I. (2020). Determinants of the intention to consume halal food, cosmetics and pharmaceutical products. Journal of Asian Finance, Economics and Business, 7(10), 831–841. https://doi.org/10.13106/jafeb.2020.vol7.no10.831 Sugiyono. (2006). Metode penelitian bisnis. Bandung: CV. Alfabeta. Windiana, L., & Putri, D. N. (2021). Pengaruh logo halal terhadap sikap dan minat beli konsumen UMM Bakery. Jurnal Ekonomi Pertanian dan Agribisnis (JEPA), 5, 1206–1216. https://doi.org/10.21776/ub.jepa.2021.005.0224. Yuliani, F. (2021). Pengaruh label halal dan citra merek terhadap keputusan pembelian produk kosmetik wardah pada rahmah cosmetic Banjarmasin (Studi kasus pada konsumen loyal produk wardah di Banjarmasin Selatan). Skripsi tidak dipublikasikan. Banjarmasin: Universitas Islam Kalimantan MAB.

Style APA, Harvard, Vancouver, ISO itp.

7

Mamounas, E. P., S. J. Anderson, T. B. Julian, D. N. Krag, D. Weaver, T. Ashikaga, S. P. Harlow i N. Wolmark. "Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32." Journal of Clinical Oncology 29, nr 27_suppl (20.09.2011): 86. http://dx.doi.org/10.1200/jco.2011.29.27_suppl.86.

Pełny tekst źródła

Streszczenie:

86 Background: In NSABP B-32 5611 women with invasive breast cancer were randomly assigned to SLNB plus axillary dissection or SLNB alone. Permanent pathologic assessment of SLNs at participating sites was designed to identify all macrometastases >2 mm (slicing SLNs at approximately 2.0 mm intervals, embedding all slices in paraffin tissue blocks, and examining one H&E-stained slide from each block). Routine use of IHC or deeper sectioning was prohibited. SLN paraffin tissue blocks from negative SLNs were later evaluated centrally for occult metastases deeper in the blocks. In this report we examine the effect of this detailed assessment on the FNR of SLNB. Methods: Routine and cytokeratin IHC stains were used at two widely spaced additional levels. Occult metastases were detected in 616 of 3884 pts (15.9%) with initially negative SLNs; 69.8% had isolated tumor-cells, 27.9% micrometastases, and 2.3% macrometastases (Weaver D, et al: N Engl J Med, 2011). Results: Previously reported FNR in B-32 was 9.8% (75 of 766 pts). Information on additional pathologic assessment was available on 72 of these 75 pts and revealed occult metastases in 23 pts (31.9%). Of those 23 pts, 14 had isolated tumor cells (61%), 7 had micrometastases (30%), and 2 had macrometastases (9%) in the SLN. Including the information from the additional pathologic assessment, the FNR of SLNB in B-32 was reduced to 6.4% (49 of 763 cases). This 35% reduction in FNR was statistically significant (p< 0.001). Among the 23 FN SLNs with occult metastases, the number of positive non-SLNs was 1 in 16 pts, 2 in 2 pts, 3 in 2 pts, 4 in 2 pts, and 6 in 1 pt. Conclusions: In the B-32 trial, more detailed assessment of the SLNs with deeper sectioning and IHC staining would have significantly reduced the FNR of SLNB by about one-third. However, this reduction would have come at the expense of a 16% increase in the rate of axillary dissection by taking occult metastases into account. Supported by NCI: U10-CA-12027, U10-CA-37377, U10-CA-69974, U10-CA-69651; and ARRA ROI CA 74137.

Style APA, Harvard, Vancouver, ISO itp.

8

Edwards, Taygen, Jane M. Alsweiler, Greg D. Gamble, Rebecca Griffith, Luling Lin, Christopher J. D. McKinlay, Jenny A. Rogers, Benjamin Thompson, Trecia A. Wouldes i Jane E. Harding. "Neurocognitive Outcomes at Age 2 Years After Neonatal Hypoglycemia in a Cohort of Participants From the hPOD Randomized Trial". JAMA Network Open 5, nr 10 (11.10.2022): e2235989. http://dx.doi.org/10.1001/jamanetworkopen.2022.35989.

Pełny tekst źródła

Streszczenie:

ImportanceNeonatal hypoglycemia is common, but its association with later neurodevelopment is uncertain.ObjectiveTo examine associations between neonatal hypoglycemia and neurocognitive outcomes at corrected age 2 years.Design, Setting, and ParticipantsExploratory cohort analysis of the Hypoglycaemia Prevention With Oral Dextrose (hPOD) randomized clinical trial was conducted. The trial recruited participants from January 9, 2015, to May 5, 2019, with follow-up between January 26, 2017, and July 31, 2021. Infants were recruited from 9 maternity hospitals in New Zealand and assessed at home or in a research clinic. Children born late preterm and at term at risk of neonatal hypoglycemia but without evidence of acute or imminent illness in the first hour after birth were screened and treated to maintain blood glucose concentrations greater than or equal to 47 mg/dL.ExposuresHypoglycemia was defined as any blood glucose concentration less than 47 mg/dL, recurrent as 3 or more episodes, and severe as less than 36 mg/dL.Main Outcomes and MeasuresNeurologic examination and tests of development (Bayley III) and executive function. The primary outcome was neurosensory impairment (any of the following: blindness, deafness, cerebral palsy, developmental delay, or executive function total score worse than 1.5 SD below the mean).ResultsA total of 1197 of 1321 (91%) eligible children were assessed at a mean of corrected age 24 months; 616 (52%) were male. Compared with the normoglycemia group, children who experienced hypoglycemia were more likely to have neurosensory impairment (111 [23%] vs 125 [18%]; adjusted risk ratio [aRR], 1.28; 95% CI, 1.01-1.60), particularly if they experienced severe episodes (30 [28%] vs 125 [18%]; aRR, 1.68; 95% CI, 1.20-2.36), but not recurrent episodes (12 [19%] vs 125 [18%]; aRR, 1.06; 95% CI, 0.63-1.80). The risk of cognitive, language, or motor delay was similar between groups, but children who experienced hypoglycemia had lower Bayley-III composite cognitive (adjusted mean difference [aMD], −1.48; 95% CI, −2.79 to −0.18) and motor scores (aMD, −2.05; 95% CI, −3.30 to −0.79).Conclusions and RelevanceIn children born at risk of hypoglycemia but otherwise well, those who experienced neonatal hypoglycemia were more likely to have neurosensory impairment at corrected age 2 years, with higher risks after severe episodes. Further research is required to determine causality.

Style APA, Harvard, Vancouver, ISO itp.

9

Rijal, Tirtha Raj, Govinda Bahadur Hamal, Purushhotam Jha i Keshab Babu Koirala. "Identification of Resistant Genotypes on Rice against Blast Disease under Field Condition at Rampur, Chitwan". International Journal of Applied Sciences and Biotechnology 5, nr 4 (24.12.2017): 505–10. http://dx.doi.org/10.3126/ijasbt.v5i4.18773.

Pełny tekst źródła

Streszczenie:

Blast disease is considered as a major limiting factor in the global rice production because of its wide distribution and destructiveness and it has been causing significant yield loss in all rice growing areas of Nepal. Host resistance is the most desirable means of managing blast, especially in developing countries. Considering the importance of this disease field screening experiment was conducted to identify resistant rice genotypes against this disease. A total of 314 and 346 rice genotypes with resistant (Sabitri) and susceptible checks (Sankarika) were evaluated under epyphytotic conditions during 2016 and 2017 summer seasons at Rampur, respectively. During 2016 disease severity varied from 1 to 9 and only five genotypes; Sabitri, IR 12L 110, WAS122-IDSA14-WASB-FKRI, IR 10F 559and IR 10F 616 were resistant, 30 moderately resistant, 150 susceptible and 129 highly susceptible against blast disease. Similarly during 2016 out of 346 genotypes, 23 resistant as ARIZE SWIFT GOLD, IR95784-21-1-1-2, NR2169-10-4-1-1-1-1-1-2, NR2169-10-2-3-1-1-1-1-1, NR2181-165-1-1-1-1-1-1-1, NR2167-48-5-1-2-1-1, NR2171-2-1-1-3-1-1-2, NR2170-5-5-1-6-1-1-3-1, NR2170-31-1-1-5-1-1-1-1, NR2167-41-1-1-3-1, NR2172-34-1-1-1-1-1-1-1, Sabitri, IR82589-B-B-114-3, IR79913-B-238-3-3, IR93823-36, IR08L 152, IR82589-B-B-51-4, IR09F 434, IR55423-01, IR94391-131-353-19-B-1-1-1-1-1, NR2154-8-1-1-1-1-1, NR 2124-43-3-1-1-1, NR2160-68-1-1-1-1-1., 72 moderately resistant, 191 susceptible and 155 were highly susceptible. Most of the highly susceptible genotypes were knocked down at the time of disease scoring.Int. J. Appl. Sci. Biotechnol. Vol 5(4): 505-510

Style APA, Harvard, Vancouver, ISO itp.

10

Peinado Acevedo, J. S., M. Calle, A. Medina, D. Jaramillo Arroyave, A. Vanegas, L. A. González, G. Vásquez, M. Restrepo Escobar i C. Muñoz. "AB0514 CALF PAIN, KEY POINT IN THE DIAGNOSIS OF POLYARTERITIS NODOSA". Annals of the Rheumatic Diseases 79, Suppl 1 (czerwiec 2020): 1554.2–1554. http://dx.doi.org/10.1136/annrheumdis-2020-eular.6578.

Pełny tekst źródła

Streszczenie:

Background:polyarteritis nodosa (PAN) is a primary systemic vasculitis that is becoming a rare disease in part by the decrease in hepatitis B virus (HBV) infection due to widespread vaccination. It is characterized by a full vast constellation of nonspecific clinical manifestations, which sometimes delays and makes it difficult to diagnose. Still, muscle involvement is a feature that could guide the clinician.Objectives:to describe the main clinical and laboratory characteristics of patients with PAN and to confirm the frequency of muscle involvement.Methods:retrospective cross-sectional descriptive study of 23 adult patients diagnosed with PAN between January 2011 and December 2018 in two high complexity hospitals in Medellin-Colombia.Results:twenty-three patients met ACR 1990 classification criteria for PAN, 52% were men with a median age of 51 (IR 36-60), 78.3% were newly diagnosed, and only two patients (8.7%) had HBV infection. General symptoms (found in 95% of the patients), cutaneous (82%), and articular (56%) were the most frequent manifestations. Among systemic symptoms, myalgia, especially calf pain, was the most common characteristic (78.3%), followed by weight loss (73.9%), fatigue (69.3%), and fever (59.3%). Laboratory findings and severity scores are shown in the table. Angiography was performed in 27.3% of patients, finding splanchnic (renal, hepatic and splenic) microaneurysms (17.4%), stenosis (13%), and renal infarction (4.3%). Fourteen patients (61%) had at least one positive biopsy documenting medium-sized artery vasculitis, mainly skin, muscle, nerve, or both; 9 (39%) had normal or inconclusive biopsy findings. All patients received high daily doses of prednisolone (50 ± 16 mg); 52.2% required cyclophosphamide, 30.4% azathioprine, 17.4% methotrexate, 8.7% rituximab, 4.3% dapsone and 4.3% plasmapheresis; acetylsalicylic acid was given to half of the patients and only one required antiviral therapy for HBV. With treatment, 87% improved; 22.7% had an infection, and 8.7% of patients died.Conclusion:myalgia was the main characteristics of our PAN patients, especially in calves, and its presence in patients with other general, skin or articular symptoms should raise the suspect of this vasculitis.References:[1]Karadag O, Jayne DJ. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol. 2018;36 Suppl 111(2):135–142.[2]Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–626.TableCharacteristicPAN patients (n=23)CRP (mean and SD in mg/dl)6.3 ± 8.51ESR (mean and SD in mm/h)84 ± 38CPK (median and IR in U/L) normal value < 18076 (66)FFS (mean)1BVAS (median and IR)17 (7)PAN: polyarteritis nodosa; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; CPK: creatine phosphokinase; FFS: five factor score; BVAS: Birmingham Vasculitis Activity Score; SD: standard desviation; IR (interquartile range)Disclosure of Interests:None declared

Style APA, Harvard, Vancouver, ISO itp.

11

Orciuolo, Enrico, Gabriele Buda, E. Mauro, E. Marturano, Domenico Pastore, Paola Della Cioppa, Giuseppe Pietrantuono i in. "Incidence of Febrile Episode During Stem Cell Mobilization (SCM) After High Dose Ciclophosphamide Chemotherapy (HD-CTX) and G-CSF (filgrastim or lenograstim) Administration in Multiple Myeloma (MM) Patients: II Interim Evaluation". Blood 112, nr 11 (16.11.2008): 4135. http://dx.doi.org/10.1182/blood.v112.11.4135.4135.

Pełny tekst źródła

Streszczenie:

Abstract Introduction: Clinical use of G-CSF in pts with high grade chemotherapy induced neutropenia does not conduce to a reduction of the incidence of febrile episodes (FE). This paradox may be explained by the acquisition of a defective chemotaxis by neutrophils (PMN) exposed to filgrastim (Fil), due to a higher adhesivity and cytoscheletric alterations. Lenograstim (Leno), a glicosilated form of G-CSF, is able to stimulate PMN production, manteining in vitro all the functional capabilities. On these bases, we hypotized that Leno may prevent FE and reduce their lasting in pts with chemotherapy derived neutropenia. Patients and methods: starting from April 2005, 105 MM pts achieving HD-CTX for SCM were enrolled in 12 Centers. Treatment plan consisted in: HD-CTX (3 or 4 g/sqm) on day 1, G-CSF (random: Fil or Leno) 30 MU/day from day +4 to +9, 60 MU/day from day +10 to the achievement of an optimal CD34+ cell count for staminoapheresis. Random, 1:1, was effectuated on the base of a generated random list. FE, significant if equal or higher than 38 °C for at least 2 different determinations, were recorded till day +30. Primary endpoint is the incidence of FE; secondary endpoints are the duration of FE, efficacy in the CD34+ cell mobilization, time to mobilization. Results: 105 pts were enrolled. All pts underwent post-chemo grade 4 neutropenia and G-CSF was administred starting from day +4. FE were recorded in 23 pts, 14 in the Fil arm (53 total pts) and 9 in the Leno arm (52 total pts). The global fever incidence was 21.9%, 26.4% with Fil and 17.3% with Leno, with a 9.1% difference. Average days with fever are 4.00 with Fil and 3.67 with Leno. Related to the neutropenia grade, 8 FE are recorded with Fil and 1 FE with Leno with absolute PMN count >500/μL (grade 4); 7 episodes with Fil vs 1 with Leno when PMN are >1000/μL (grade 3–4). CD34+ SCM occurs in after an average time of 10.3 day with Fil and 9.8 day with Leno, with an higher absolute count with Leno when compared to Fil: 131.9 CD34+/μL (range 40–640) vs 111.6 (range 40–616) CD34+/μL. Conclusions: Leno is associated with a reduced incidence (17.3% vs 26.3%) of FE in MM patients undergoing to HD-CTX and SCM when compared to Fil. FE are recorded with Fil even in presence of PMN confirming the functional block by Fil on PMN documented in vitro. CD34+ mobilization occurs shorter and with higher efficiency with Leno when compared to Fil. On these evidences, patients’ enrollment will continue to 180 to validate these results.

Style APA, Harvard, Vancouver, ISO itp.

12

Piulats, Josep M., Arun A. Azad, A. Douglas Laird, Nobuaki Matsubara, Karim Fizazi, Neal D. Shore, Lawrence Karsh i in. "Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)". Cancer Research 84, nr 7_Supplement (5.04.2024): CT018. http://dx.doi.org/10.1158/1538-7445.am2024-ct018.

Pełny tekst źródła

Streszczenie:

Abstract Background: In TALAPRO-2 (NCT03395197), pts unselected for homologous recombination repair (HRR) gene mutations (muts) received TALA + ENZA or PBO + ENZA in 1L mCRPC. TALA + ENZA significantly improved radiographic progression-free survival (rPFS). Previous analyses focused on the association of tumor HRR gene muts with outcome; here, we examined TALA + ENZA efficacy in pts with ≥1 non-HRR gene mut with/without HRR gene muts. Methods: This is a post-hoc exploratory agnostic analysis of a TALAPRO-2 dataset of prospectively collected/retrospectively analyzed plasma ctDNA (FoundationOne®Liquid CDx). Response was assessed per RECIST v1.1. Results: Overall, 616 pts in the intent-to-treat population had non-HRR gene muts with/without HRR gene muts; 98 (16%) pts had TMPRSS2-ERG fusions. In these 616 pts, TALA + ENZA improved rPFS vs PBO + ENZA (Table). TALA + ENZA improved rPFS in pts with TMPRSS2-ERG, RB1, or MLL2 muts, and objective response rates (ORR) in pts with TMPRSS2-ERG or RB1 muts and measurable disease at baseline (the association of MLL2 with enhanced rPFS was lost without TMPRSS2-ERG, not shown). In pts with non-HRR gene muts and no HRR gene muts (n=427), TALA + ENZA showed improvement in rPFS vs PBO + ENZA. Enhanced rPFS benefit with TALA + ENZA vs PBO + ENZA was noted in pts with TMPRSS2-ERG, RB1, or MLL2 muts, but TMPRSS2-ERG ORRs were similar across treatment arms. Conclusions: TALA + ENZA improved outcomes compared with PBO + ENZA in patients with muts in specific non-HRR genes (regardless of HRR gene muts). TMPRSS2-ERG and RB1 emerged as candidate predictive biomarkers for differential efficacy favoring TALA + ENZA vs PBO + ENZA. PARP inhibitors may induce a synthetically lethal interaction with TMPRSS2-ERG-mediated inhibition of non-homologous end joining and help overcome RB1-mediated ENZA resistance. ≥1 non-HRR gene muts ≥1 non-HRR gene muts with no HRR gene muts Median rPFS, mo HR (95% CI) Median rPFS, mo HR (95% CI) Gene mutation TALA + ENZA (N=310) PBO + ENZA (N=306) TALA + ENZA (N=218) PBO + ENZA (N=209) Any non-HRR NR 19.3 0.63 (0.50–0.80) NR 22.5 0.66 (0.49–0.89) TMPRSS2-ERG, [n] 25.9 [n=43] 11.0 [n=55] 0.36 (0.20–0.64) 19.4 [n=32] 11.0 [n=44] 0.40 (0.20–0.76) MLL2, [n] 18.2 [n=20] 13.8 [n=20] 0.43 (0.19–0.98) NR [n=8] 17.2 [n=11] 0.50 (0.14–1.74) RB1, [n] 9.8 [n=14] 1.9 [n=8] 0.22 (0.07–0.73) 10.8 [n=6] 1.8 [n=3] 0.40 (0.05–2.92) ORR, % (n/N)a OR (95% CI) ORR, % (n/N)a OR (95% CI) TALA + ENZA (N=96) PBO + ENZA (N=105) TALA + ENZA (N=62) PBO + ENZA (N=75) TMPRSS2-ERG 56 (13/23) 41 (7/17) 0.54 (0.12–2.27) 53 (9/17) 47 (7/15) 0.78 (0.16–3.85) MLL2 64 (7/11) 70 (7/10) 1.33 (0.15–12.60) ND ND ND RB1 62 (5/8) 0 (0/6) 0.00 (0.00–0.75) ND ND ND CI, confidence interval; HR, hazard ratio; mo, months; ND, not displayed (combined prevalence <10 pts); NR, not reached; OR, odds ratio. aMeasurable disease at baseline Citation Format: Josep M. Piulats, Arun A. Azad, A. Douglas Laird, Nobuaki Matsubara, Karim Fizazi, Neal D. Shore, Lawrence Karsh, Glenn Liu, Andre P. Fay, Joan Carles, Robert J. Jones, Eric Voog, Stefanie Zschäbitz, Ugo De Giorgi, Steven M. Yip, Xinmeng Jasmine Mu, Xun Lin, Arne Engelsberg, Neeraj Agarwal. TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT018.

Style APA, Harvard, Vancouver, ISO itp.

13

Kuhn, Matthias, Andreas Thiel i Peter Böger. "The 9-kDa Phosphoprotein Involved in Photoinhibition". Zeitschrift für Naturforschung C 43, nr 5-6 (1.06.1988): 413–17. http://dx.doi.org/10.1515/znc-1988-5-615.

Pełny tekst źródła

Streszczenie:

Photosystem-II particles exhibit strong photoinhibition. Short-term illumination of photosystem- II particles with high-intensity light (5000 μE/m2 × s) leads to a typical change of the protein pattern on SDS-PAGE. Two proteins are mainly affected, namely the well-described 32-kDa herbicide-binding protein which probably is degraded [1] and, first published here, the 9-kDa phosphoprotein, whose function in the PS-II complex is still unknown. This protein is not degraded, but seems to be linked to other polypeptides of the PS-II complex. During light treatment new bands of 23, 41, 50 and 54 kDa appear in the protein pattern of SDS-PAGE. A monospecific antiserum was produced against the 9-kDa phosphoprotein to investigate its fate. After light treatment the antibodies reacted with new proteins of higher molecular weights, most pronounced with a 23-kDa and a 41-kDa peptide.

Style APA, Harvard, Vancouver, ISO itp.

14

Mirza, Sayeef, Seongseok Yun, Najla Al Ali, Hannah Shin, Joseph Luke O'Neill, Daniel Schwartz, Amra Kuc i in. "Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience". Blood 132, Supplement 1 (29.11.2018): 5880. http://dx.doi.org/10.1182/blood-2018-99-120332.

Pełny tekst źródła

Streszczenie:

Abstract INTRODUCTION Thrombotic episodes represent significant morbidity and mortality in patients with hematologic malignancies and may be influenced by several risk factors. Current predictive and prognostic models do not take into account several risk factors. Furthermore, prophylactic and therapeutic management of thrombosis remains to be standardized for patients with AML. Few studies report the impact of catheters to the likelihood of thrombosis. We comprehensively report our institution's experience with thrombosis in AML patients. METHODS The Total Cancer Care (TCC) database was used to retrospectively chart review patients with histologically confirmed AML from 2000 to 2018. Several parameters were extracted including but not limited to history of thrombosis and recurrences, chemotherapy regimens, and laboratory values for significant events. All statistical analyses were performed using SPSS v24.0 and GraphPad Prism 7. RESULTS: A total of 1101 patients were diagnosed with either de novo (516, 46.87%) or secondary (584, 53.04%) AML. The median age of diagnosis was 75 years (52, 95) and men were the majority, 726 (65.94%). In terms of cytogenetics, 25 (2.27%) had good/favorable, 616 (55.95%) had intermediate, and 334 (41.75%) had poor cytogenetics. At the time of diagnosis, CBC revealed median WBC of 3 (0, 420), ANC 1 (0, 132), Plt 52 (1, 996), and hgb 9 (1, 15). Median ECOG score was 1. 159, 14.4% patients had a history of thrombosis prior to AML diagnosis; with a median of 1 episode of thrombosis (1, 4). After AML diagnosis 70 patients had one episode of thrombosis, 9 had two episodes, and 2 patients had three recurrent episodes. As far as the first-line induction therapy, 247 (22.43%) patients received 7+3, 12 (1.08%) received CLAG, 36 (3.27%) received hypomethylating agents, and the remaining 227 (2.06%) received other therapies such as clinical trials or off-label drugs. Repeat cycles of therapies were also recorded. In terms of growth factor use after AML diagnosis, 132 (11.99%) used EPO, 209 (18.98%) G-CSF, 32 (2.90%) GM-CSF, and 778 (70.66%) used any other growth factor not mentioned. Out of the 139 episodes of thrombosis, 81 (58.3%) were venous, and 58 (41.7%) were arterial. Among the venous, 45 (55.6%) were lower extremities, 21 (25.9%) were upper extremities, and 10 (12.3%) were pulmonary embolus. Among the arterial thrombosis, 27 (46.6) were coronary events, 23 (39.7%) were cerebral events. Only 15 patients had catheter-associated thrombosis events, 11 (73.3%) were PICC, and 2 (13.3%) were Port lines or central lines. In terms of management, 39 patients were on temporary anticoagulation, 60 patients were on indefinite anticoagulation, and 522 were not on any anticoagulation. In terms of complications, 3 patients had minor bleeding, 1 had major bleeding, 2 had HIT and the large majority of 419 had no complications of anticoagulation. CONCLUSIONS: Thrombosis both venous and arterial events manifest during treatment for leukemias. PICCs lines are associated with more catheter associated thrombosis events than ports. Further prospective studies are needed to evaluate the risk of both arterial and venous thrombosis in patients with acute leukemia. Further risk mitigation strategies are needed. Disclosures Komrokji: Novartis: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Speakers Bureau; Celgene: Honoraria, Research Funding; Novartis: Honoraria, Speakers Bureau.

Style APA, Harvard, Vancouver, ISO itp.

15

Staron, Andrew, Luke Zheng, Gheorghe Doros, Lawreen H. Connors i Vaishali Sanchorawala. "A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis". Blood 138, Supplement 1 (5.11.2021): 155. http://dx.doi.org/10.1182/blood-2021-151804.

Pełny tekst źródła

Streszczenie:

Abstract Background: Natural history studies, which describe changing disease outcomes under real-world clinical practice, can help support drug development for rare diseases by defining appropriate endpoints for clinical trials. The current study provides natural history information on survival and mortality in light chain (AL) amyloidosis, a rare disease that was historically considered inevitably fatal. With the recent expansion of effective therapeutics, patients with this disease are living longer, which in turn necessitates a better understanding of the factors leading to death in later disease course. Aims: To evaluate (1) trends in overall survival (OS) over time and (2) primary causes of death across the course of AL amyloidosis disease. Methods: We identified 2,337 patients diagnosed with systemic AL amyloidosis between 1980 and 2019 from the prospectively maintained database at the Boston University Amyloidosis Center (ClinicalTrials.gov Identifier: NCT00898235). Disease outcomes were analyzed according to date of tissue diagnosis: 1980-1989 (era 1, n = 185), 1990-1999 (era 2, n = 575), 2000-2009 (era 3, n = 865) and 2010-2019 (era 4, n =712). Survival information was verified through yearly clinical evaluations, contact by phone/letter for patients who did not return for follow-up, or the U.S. Social Security Death Index if contact was not established. We defined deaths as AL amyloidosis-related when clinical data indicated organ progression or complications from plasma cell-directed therapy. Deaths occurring while in remission, off treatment and without evidence of organ progression were considered disease-unrelated. Results: OS increased steadily across eras 1-4 with median values of 1.4, 2.6, 3.3 and 4.6 years, respectively (P < .001). Six-month mortality decreased over time from 23% to 13%. Notably, median age at diagnosis increased from 59 to 63 years (P < .001), and time interval to diagnosis from patient-reported symptom onset shortened from 10 months to 6 months (P = .065). At data cutoff (October 2020), 1,660 (71%) patients had died. Primary cause of death was ascertainable for 1,160 (70%) cases. Organ failure was most common, accounting for 564 (49%) deaths, amongst which cardiac failure predominated. Sudden unexpected death was the next most frequent cause, contributing to 266 (23%) deaths. Together, cardiac failure and sudden death decreased in proportion with longer survival from diagnosis, representing 67% (236/354) of deaths occurring within ≤6 months; 56% (322/575) within >6 months to ≤5 years; 36% (54/151) within >5 years to ≤10 years; and 36% (29/80) after >10 years (P < .001). Meanwhile, renal failure and infections emerged as important causes of later-occurring deaths. There was sufficient data on 1,243 (75%) deaths to assign relation to AL amyloidosis. The vast majority were disease-related. Yet, disease-unrelated deaths increased with longer survival from diagnosis, accounting for 2% (9/373) of deaths occurring within ≤6 months; 8% (48/616) within >6 months to ≤5 years; 16% (25/161) within >5 years to ≤10 years; and 29% (27/93) after >10 years (P < .001). Conclusions: Under changing standards of care, OS improved and early mortality declined over the last 40 years, supporting a much-improved outlook for current and future patients with AL amyloidosis. Cardiac failure and sudden deaths decreased across the course of disease. Even so, progression of amyloidosis remained a top cause of death even among long-term survivors. Figure 1 Figure 1. Disclosures Sanchorawala: Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity's Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity's Board of Directors or advisory committees; Regeneron: Membership on an entity's Board of Directors or advisory committees; Proclara: Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.

Style APA, Harvard, Vancouver, ISO itp.

16

Largeaud, Laetitia, Sarah Bertoli, Emilie Berard, Suzanne Tavitian, Muriel Picard, Stephanie Dufrechou, Naïs Prade i in. "Genomics of Hyperleukocytic Acute Myeloid Leukemia". Blood 138, Supplement 1 (5.11.2021): 1294. http://dx.doi.org/10.1182/blood-2021-147497.

Pełny tekst źródła

Streszczenie:

Abstract Hyperleukocytic AML (HL-AML) is characterised by a high risk of early death and poor prognosis. We previously reported the impact of adding dexamethasone (DEX) to intensive chemotherapy in this situation (Bertoli et al, Haematologica 2018). The aim of this study was to give a comprehensive description of HL-AML at the molecular level and to investigate interactions between molecular lesions and DEX treatment. In the earlier study which included 160 patients (pts) (18 - 75 years old) with WBC > 100 x 10 9/L or > 50 x 10 9/L with leukostasis symptoms, multivariate analyses had shown that DEX treatment was significantly associated with better DFS, EFS and OS (Bertoli S, Haematologica 2018). In this pre-midostaurin registration patient cohort (2004-2015), no pt received a FLT3 inhibitor. Diagnostic samples for NGS analyses were available for 154 pts (96.3% of the initial cohort), 59 pts who received DEX with 3+7 induction chemotherapy and 95 pts who did not. The presence of FLT3-ITD was tested as described (Larochelle O, Oncotarget 2011). CEBPA screening was performed by Sanger sequencing (Pabst T, Nat Genet 2001). Extended DNA resequencing was performed using an Illumina NextSeq500 and Sureselect target enrichment system (Agilent, Santa Clara, CA), targeted on the complete coding regions of 79 genes commonly mutated in myeloid malignancies. The cytogenetic risk was favorable, intermediate or adverse in 15 (9.7%), 121 (78.6%) and 18 (11.7%) pts. A total of 616 mutations were identified with an average of 4 mutations/pt (0 to 10 mutations/pt). Only one pt with inv(16) had no mutation detected. The most frequently mutated genes were FLT3 (62%), NPM1 (53%), DNMT3A (34%), TET2 (23%), NRAS (21%), IDH2 (12%), WT1 (11%), PTPN11 (10%), RUNX1 (10%), KRAS (9%) and IDH1 (9%). Of the 71 pts (46%) with FLT3-ITD mutations, 32 (45.1%) had an allelic ratio > 0.5. Mutations in the RAS pathway were detected in 67 pts (44%), including NRAS (n=32, 21%), PTPN11 (n=15, 10%), KRAS (n=14, 9%) and NF1 (n=6, 4%). Overall, a large majority of pts had mutations in signaling genes (n=131, 85.1%). Drug-actionable mutations such as FLT3 (n=96), IDH2 (n=17), IDH1 (n=14), KIT (n=11), TP53 (n=4) or JAK2 (n=1) were detected in 113 patients (73.4%). In patients with FLT3 mutations (n=96), 12 had co-mutations in IDH1 and 12 pts had co-mutations in IDH2. The prognostic impact of the AML genomic classification (Papaemmanuil E, NEJM 2018), NPM1/FLT3-ITD/DNMT3A status, functional gene categories (Bullinger L, JCO 2017) ELN 2017 classification and individual genes was assessed. AML with inv(16)/CBFB-MYH11, CEBPA mutations, NPM1 mutations and myeloid transcription factor gene fusions or mutations were significantly and independently associated with better OS whereas the chromatin-modifying gene subset, NPM1/FLT3-ITD/DNMT3A triple mutations, ELN 2017-adverse risk and DNMT3A mutations were associated with poorer OS. NPM1/FLT3-ITD/DNMT3A triple mutations were observed in 25 pts (16%), 23 of whom died. Compared to this triple mutated subset, lower HRs were found in double mutant NPM1mut/FLT3-ITD (HR, 0.43; 95%CI: 0.19-0.97; P=0.041) or NPM1mut/DNMT3Amut (HR, 0.47; 95% CI: 0.21-1.07; P=0.074). The prognostic impact of each individual gene was assessed using the LASSO statistical method. CBFB-MYH11 (HR, 0.10; 95% CI: 0.02-0.43; P=0.002), CEBPA (HR, 0.22; 95% CI: 0.09-0.53; P=0.001), NPM1 (HR, 0.33; 95% CI: 0.19-0.58; P<0.001) and surprisingly, RUNX1 mutations (HR, 0.40; 95% CI: 0.18-0.92; P=0.030) were independently associated with better OS. DNMT3A mutations were independently predictive of poor OS (HR, 1.76; 95% CI: 1.02-3.03; P=0.043). Median DFS (13.6 months vs 66.3, P=0.002), EFS (11.3 vs 39.4, P=0.002) and OS (18.3 vs not reached, P=0.006) were significantly better in pts who received DEX. In multivariate analyses, no significant interaction between DEX and classifications or gene mutations was found, indicating that the effect of DEX did not differ significantly between the various genetic subsets. This may be due to insufficient numbers or DEX may have broader effects on biological phenomena such as inflammation. Since more than 80% of pts have mutations in signaling genes, inhibition of signaling pathways could improve prognosis of HL-AML. The impact of midostaurin will be interesting to analyse in this setting. Inhibition of the RAS pathway could also be a valuable avenue. Figure 1 Figure 1. Disclosures Bertoli: Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees. Tavitian: Novartis: Consultancy. Vergez: Pierre Fabre Laboratory: Research Funding; Roche: Research Funding. Huguet: Novartis: Other: Advisor; Jazz Pharmaceuticals: Other: Advisor; Celgene: Other: Advisor; BMS: Other: Advisor; Amgen: Other: Advisor; Pfizer: Other: Advisor. Delabesse: Novartis: Consultancy; Astellas: Consultancy. Recher: Daiichi Sankyo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Honoraria; Janssen: Honoraria; Jazz: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; MaatPharma: Research Funding; Macrogenics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. OffLabel Disclosure: dexamethasone in hyperleukocytic AML.

Style APA, Harvard, Vancouver, ISO itp.

17

Bello, Ihosvany Fernández, Mayte Álvarez Román, Elena G. Arias Salgado, Monica Martin Salces, Miguel Canales, Victor Jimenez Yuste i Nora V. Butta. "Procoagulant Status In Patients With Immune Thrombocytopenia". Blood 122, nr 21 (15.11.2013): 3528. http://dx.doi.org/10.1182/blood.v122.21.3528.3528.

Pełny tekst źródła

Streszczenie:

Abstract Introduction Immune thrombocytopaenia (ITP) is an acquired immune-mediated disorder characterized by mild to severe thrombocytopaenia caused by autoantibodies against platelet proteins. Bleeding risk in patients with ITP is increased with platelet counts less than 20 or 30 x 109/L. However, patients with ITP often have few bleeding symptoms despite very low platelet counts suggesting the existence of compensatory mechanisms. Moreover, an increased risk for thrombosis in patients with ITP has been described (Nørgaard M, 2012). It has been recently reported that increased production of platelet- and red cells-derived microparticles (MP) might be one of the causes of increased thrombotic risk in ITP patients (Sewify, 2013). Objective The aim of this study was to evaluate the microparticle-associated and plasma procoagulant activities in ITP patients with thrombocytopaenia. Methods Sixty-eight patients with chronic ITP and platelet count less than 50 x 109/L and twenty-two healthy controls were included. Platelet counts were determined with a Coulter Ac. T Diff cell counter (Beckman Coulter, Madrid, Spain). Citrated blood was centrifuged at 1,500 g for 15 min at 23°C. Platelet-poor plasma obtained was additionally centrifuged twice at 23°C (15 min at 1,500 g, and 2 min at 13,000 g) and aliquots were stored at -70ºC until analysis. Phosphatidylserine-MP (Ph-MP) and tissue factor-MP (TF-MP) dependent procoagulant activities were determined with the ZYMUPHEN kits (Hyphen BioMed, Neuville sur Oise, France) following the manufacturer’s instructions. Plasma thrombin generation was measured using the Calibrated Automated Thrombogram (CAT) test as described by Hemker et al (2000) at a final concentration of 1 pM tissue factor and 4 μM phospholipids (PPP-Reagent LOW, Thrombinoscope BV, Maastricht, The Netherlands). We evaluated the endogenous thrombin potential (ETP, the total amount of thrombin generated over time); the lag time (the time to the beginning of the explosive burst of thrombin generation); the peak height of the curve (the maximum thrombin concentration produced); and the time to the peak. To test resistance to protein C, CAT experiments were performed without and with the addition of thrombomodulin (TM) (PPP and PPP with thrombomodulin reagents, Thrombinoscope BV, Maastricht, The Netherlands). Results were expressed as the ratio [(ETP with TM)/(ETP without ETP)]x100. Results were expressed as mean±SD. Comparisons of quantitative variables were made with Mann-Whitney test and correlations with Spearman test. Values of p≤0.05 were considered statistically significant. Results Ph-MP associated procoagulant capacity in ITP patients was higher than in controls (p<0.05) whereas MP-TF associated procoagulant activity was practically negligible in both groups. Plasma procoagulant activity was higher in ITP patients than in controls (ETP: 1604±616 nM x min in ITP patients and 1302±416, p=0.012 in controls; Peak: 328±123 nM in ITP patients and 203±74 nM in controls, p<0.001). We tested whether the higher procoagulant activity of plasma from ITP patients was due to a resistance to protein C. We observed that the mean Ratio value in ITP patients was slightly higher than the mean Ratio of controls (60±18 and 50±13 respectively, p=0.034). Despite this significant difference in the Ratio, no correlation was found between this value and the CAT parameters. Conclusion ITP patients with thrombocytopaenia had a higher Ph-MP associated and plasma procoagulant activity than controls. The fact that the increased MP-procoagulant activity was not accompanied by a higher TF-MP associated procoagulant activity brings further support to the previous observation that MPs in ITP patients are from platelets and red cells, as both cells express very low levels of TF (Sewify, 2013). Regarding the increased plasma procoagulant capacity observed in ITP patients, our results suggest that resistance to protein C does not seem to be the main mechanism involved. References • Nørgaard M. Thromb Res. 2012;130 Suppl 1:S74-75. • Sewify EM, et al. Thromb Res. 2013;131:e59-63. Hemker HC, et al. Thromb Haemost 2000;83:589-9. Disclosures: No relevant conflicts of interest to declare.

Style APA, Harvard, Vancouver, ISO itp.

18

Reeder, Craig B., Donna E. Reece, Vishal Kukreti, Joseph R. Mikhael, Christine Chen, Suzanne Trudel, Kristina Laumann i in. "A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity." Blood 114, nr 22 (20.11.2009): 616. http://dx.doi.org/10.1182/blood.v114.22.616.616.

Pełny tekst źródła

Streszczenie:

Abstract Abstract 616 Background: We have shown the three drug combination of cyclophosphamide, bortezomib and dexamethasone (CyBorD) to be highly active therapy in newly diagnosed myeloma while allowing stem cell harvest and transplantation (Reeder et al. Leukemia 2009; 23:1337-1341). However, twice weekly bortezomib and high dose dexamethasone have been shown to cause significant toxicities. In a prospective Phase II we modified CyBorD by using bortezomib once weekly and reducing the dexamethasone to “low dose dex” after the first two cycles in an attempt to reduce toxicity (cohort 2). We report the efficacy and toxicity of this modified regimen and compare the results to standard CyBorD (cohort 1). Patients and methods: 63 untreated symptomatic patients were enrolled on this Phase II trial (33 on cohort 1 and 30 on cohort 2). All are evaluable for response and toxicity. Treatment on cohort 2 consisted of oral cyclophosphamide 300 mg/m2 and IV bortezomib 1.5 mg/m2 days 1, 8, 15 and 22 and dexamethasone 40 mg by mouth days 1-4, 9-12, 17-20 in cycles 1 and 2, then 40 mg po days 1, 8, 15, 22 in cycles 3 and beyond. Cohort 1 used standard dosing of bortezomib and high dose dexamethasone throughout. Each cycle was 28 days. Acyclovir and a quinolone antibiotic prophylaxis were routinely used. Patients were evaluated for response and toxicity every cycle and were offered stem cell harvest and transplant after the 4th cycle but could continue up to 12 cycles maximum. Results: The median age for all 63 patients was 61 (36-74) years and 48% were female. Durie-Salmon stages were 47% II and 50% III and ISS stages I 43%, II 36%, and III 21%. Twenty-four percent of patients were genetic high risk (t(4;14) or deletion 17). Cohorts I and II were matched for age, gender and ECOG PS. ISS stages were higher in cohort 1 than cohort 2 (II/III 67% vs. 44%). The intent to treat (ITT) ORR (≥PR) for all 63 patients (cohorts 1 and 2) is 90% with 60% ≥VGPR. For cohort 2 (modified CyBorD) the ITT overall response (≥PR) was 93% (CR: 5, nCR: 7, VGPR: 6, PR: 10) with 60% ≥VGPR and 40% ≥ nCR. Those completing all 4 cycles of therapy had 92% ORR (24/26) and 65% (17/26) ≥VGPR. A comparison of response rates in cohorts 1 and 2 is shown in table 1. These high and comparable response rates were associated with fewer grade 3+ adverse events (AE's) than in cohort 1 (37% vs. 48%) and no grade 3 peripheral neuropathy (PN). The median follow-up for all 63 patients is 12.4 (2.8-29.2) months and 95% of patients are alive with 87% free from progression. Conclusions: Modified CyBorD with weekly bortezomib and reduced dexamethasone retains the high activity seen in standard CyBorD, but is less toxic and more convenient. Interestingly, this modified regimen allowed higher overall doses of bortezomib (5.2 vs. 6.0 mg/m2 per cycle) yet overall neuropathy rates were similar. This combination of a weekly alkylating agent with bortezomib and dexamethasone is well tolerated and produces high response rates in newly diagnosed patients with multiple myeloma. Disclosures: Reeder: Millennium (MPI): Research Funding; Celgene: Research Funding. Reece:Ortho Biotech: Honoraria, Research Funding. Chen:Celgene: Honoraria, Research Funding; Ortho Biotech: Honoraria. Hentz:Millennium (MPI): Research Funding. Fonseca:Otsuka: Consultancy; BMS: Consultancy; Amgen: Consultancy; Medtronic: Consultancy; Genzyme: Consultancy. Bergsagel:Merck: Research Funding; Amgen: Consultancy; Genentech: Consultancy; Celgene: Consultancy. Stewart:Proteolix: Honoraria; Millennium (MPI): Research Funding.

Style APA, Harvard, Vancouver, ISO itp.

19

Bogucki, David E., i James L. Charlton. "A non-enzymatic synthesis of (S)-(−)-rosmarinic acid and a study of a biomimetic route to (+)-rabdosiin". Canadian Journal of Chemistry 75, nr 12 (1.12.1997): 1783–94. http://dx.doi.org/10.1139/v97-612.

Pełny tekst źródła

Streszczenie:

The synthesis of (S)-(−)-rosmarinic acid (30) in 9% overall yield is described. The synthesis was achieved by a convergent route in which 3-(3′,4′-dihydroxyphenyl)-(S)-lactic acid (23) and caffeic acid (25), both appropriately protected, were coupled to produce a pentaallyl precursor 29, which was then deprotected to give (S)-(−)-rosmarinic acid (30). A triallyl derivative 35 was similarly prepared and converted to (+)-rabdosiin (41) and its (1R,2S) isomer (42) via a biomimetic oxidative free radical coupling–cyclization followed by deallylation. The coupling–cyclization gave a ratio of rabdosiin diastereomers unlike that found in nature. A preliminary study showed that methyl (R)-mandelyl sinapate (15) could be dimerized diastereoselectively to give a 1,2-trans thomasidioate diester (16). Keywords: rabdosiin, rosmarinic acid, lignan, oxidative coupling.

Style APA, Harvard, Vancouver, ISO itp.

20

Setiawan, Laksono, i Nurbaedah Nurbaedah. "IMPLEMENTASI KEPUTUSAN KAPOLRI NO. 613/ III/ 2021 TERHADAP LIDIK SIDIK DAN KEADILAN KORBAN TINDAK PIDANA DI WILAYAH HUKUM POLRES NGANJUK". Mizan: Jurnal Ilmu Hukum 12, nr 1 (15.07.2023): 114. http://dx.doi.org/10.32503/mizan.v12i1.4057.

Pełny tekst źródła

Streszczenie:

Kapolri jenderal Listyo sigit Prabowo mengeluarkan keputusan terkait dengan 1.062 Polsek di seluruh Indonesia tidak bisa melakukan proses penyidikan. Dalam keputusan kapolri nomor 613/ III/ 2021 tanggal 23 Maret 2021 tentang Penunjukan kepolisian sektor untuk Pemeliharaan Keamanan dan ketertiban Masyarakat Pada daerah tertentu (Tidak melakukan Penyidikan) ada 9 (sembilan) Polsek di jajaran Polres Nganjuk yang tidak melakukan Penyidikan. Diketahui bahwa locus delicti dan tempus delicti memiliki pengaruh strategis terkait Operasionalisasi dari tindak pidana, pertanggung jawaban pidana, dan pemidanaan. Rumusan masalah meliputi: (1) Bagaimanakah Implementasi keputusan kapolri nomor 613/ III/ 2021 untuk 9 Polsek jajaran Polres Nganjuk terhadap penyelidikan dan penyidikan? (2) Apakah terpenuhi keadilan korban tindak pidana di 9 Polsek jajaran Polres Nganjuk yang tidak melakukan Penyidikan berdasarkan Tempus delicti dan Lotus delicti?Tujuan penelitian ini adalah : (a). Untuk menganalisa aplikasi keputusan kapolri nomor nomor 613/ III/ 2021 untuk 9 Polsek jajaran Polres Nganjuk pada Penyidik dan Penyidik pembantu yang bertujuan untuk akselerasi penyelesaian perkara. (b).Untuk menganalisa rasa keadilan yang dialami korban Tindak pidana di Sembilan Polsek jajaran polres Nganjuk. Metode penelitian ini dilakukan dengan penelitian empiris atau social legal research. Metode social legal research. Hasil Penelitian: Perbandingan data anev gangguan kamtibmas terlihat adanya penyelesaian perkara yang signifikan. Setelah adanya Keputusan kapolri no. 613/III/2021 tunggakan kasus unit reskrim Polres nganjuk dan polsek jajaran sebesar 21 %. Untuk rumusan masalah no 2 ternyata tidak terpenuhi keadilan korban tindak pidana di sembilan Polsek jajaran Polres Nganjuk yang tidak melakukan Penyidikan berdasarkan Tempus delicti dan Lotus delicti, dari hasil kuesioner, 30 responden 84% menjawab tidak puas dengan mayoritas masukan dan saran tahap lidik dan sidik tetap dilaksanakan di polsek dimana TKP tersebut terjadi.

Style APA, Harvard, Vancouver, ISO itp.

21

Quittet, Philippe, Mohamed Hamidou, Bernard Bonnotte, Olivier Fain, Kerry Dillingham i Georg Kreuzbauer. "Romiplostim for the Treatment of Adults with Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in France – Interim Results From a Large Observational Study". Blood 120, nr 21 (16.11.2012): 4643. http://dx.doi.org/10.1182/blood.v120.21.4643.4643.

Pełny tekst źródła

Streszczenie:

Abstract Abstract 4643 Background: The thrombopoietin-receptor agonist (TPOra) romiplostim is recommended for second-line treatment of adult ITP (Provan, Blood 2010). Romiplostim registration studies were conducted in selected patient (pt) populations and may not reflect clinical practice. Moreover, regional variations may exist in the clinical utility of romiplostim. A recent French study enrolled adult ITP pts failing previous treatments and receiving romiplostim on a compassionate use basis before commercial availability (Khellaf, Blood 2011). We report interim data from French pts enrolled in a large observational study of romiplostim use in clinical practice, with broader inclusion criteria. Methods: This ongoing study enrolls ITP pts ≥18 years old, who have received romiplostim in clinical practice. Pts participating in another study, who initiated romiplostim prior to commercial launch or received other TPOra or related products are excluded. Data recorded as per clinical practice is collected for up to 2 years following romiplostim initiation. Study outcomes include pt characteristics (at romiplostim initiation), romiplostim dose, adverse drug reactions (ADRs) and bleeds, summarized for pts meeting the eligibility criteria (Full Analysis Set; FAS). Amgen (Europe) GmbH funded the study and medical writing assistance. Results: As of February 2012, 86 (95%) of 91 pts enrolled in France were included in the FAS. Of these, 59% (51/86) remained on study, 31% (27/86) had completed the 2-year observation period and 9% (8/86) had withdrawn (death, 6 [7%]; lost to follow-up, 2 [2%]). At romiplostim initiation, median (Q1, Q3) age, weight and platelet count were 65.0 (48.0, 77.0) years, 74.00 (62.20, 84.00) kg and 18.0 (7.0, 31.0) × 109/L; 38% (33/86) of pts had been diagnosed with ITP for < 1 year (median [Q1, Q3] time from diagnosis, 3.04 [0.51, 13.04] years), 74% (64/86) had received ≥3 prior ITP therapies, 71% (61/86) had received prior rituximab, 30% (26/86) were splenectomised and 52% (45/86) female. Romiplostim was initiated at 1 and ≥3 μg/kg/week in 63% (54/86) and 24% (21/86) of pts; 36% (31/86) of pts stopped romiplostim before the end of the 2-year observation period, with requirement for alternative therapy (11 [13%]), haemostatic platelet count/no further treatment necessary (6 [7%]; last platelet count before romiplostim stopped, 68–616 × 109/L; 1 pt splenectomised, 4 had ITP disease duration of <1 year, all had received 3–5 prior therapies, 1 later received corticosteroids) and ADR (4 [5%]) the most commonly specified reasons. Median (Q1, Q3) romiplostim exposure was 55.1 (29.9, 100.3) weeks (maximum 106 weeks); median follow-up after romiplostim initiation was 20.40 (14.50, 24.10) months. Median (Q1, Q3) average weekly dose over the observation period was 2.6 (1.4, 4.2) μg/kg/week, and 3.02 [2.00, 5.00] and 2.00 [1.14, 3.02] μg/kg/week after 1 and 2 years of treatment (months 10–12 [n=48] and 22–24 [n=23], respectively). Median platelet counts rose rapidly during the first 4 weeks of treatment and remained >50 × 109/L thereafter (Figure). Grade ≥3 bleeds were rare and occurred at a lower rate after romiplostim initiation (Table). The most commonly reported ADRs were thrombocytosis, asthenia, myalgia and headache (9.7–3.2 events per 100 pt-years). Three pts reported a total of 6 serious ADRs: pulmonary embolism, 2 events; deep vein thrombosis, drug ineffective, myelofibrosis (initial disease diagnosis inconsistent with ITP, myelofibrosis more likely due to MDS), and thrombocytosis (platelets 477 × 109/L), 1 event each. No fatal ADRs were reported. Summary/conclusions: This study provides further insight into the clinical utility of romiplostim in France. At an interim analysis, pts tended to have less chronic disease than those enrolled in a previous observational study (Khellaf, Blood 2011). With lower doses than reported by Khellaf, and no new safety signals, pts achieved sustained increases in platelet counts and experienced a lower rate of grade ≥3 bleeds following romiplostim initiation. Disclosures: Dillingham: Amgen: Employment, Equity Ownership. Kreuzbauer:Amgen: Employment, Equity Ownership.

Style APA, Harvard, Vancouver, ISO itp.

22

Hinton, A., E. Sears, S. Lopez-Pintado i J. Zuckerman. "614 Time between clinic visits of individuals with cystic fibrosis: patterns across the lifespan". Journal of Cystic Fibrosis 22 (październik 2023): S327—S328. http://dx.doi.org/10.1016/s1569-1993(23)01536-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

23

Koreth, John, Haesook T. Kim, Kyle T. Jones, Carol G. Reynolds, Marie J. Chammas, Katherine Dusenbury, Jennifer Whangbo i in. "Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates". Blood 124, nr 21 (6.12.2014): 41. http://dx.doi.org/10.1182/blood.v124.21.41.41.

Pełny tekst źródła

Streszczenie:

Abstract Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) results from incomplete reconstitution of immune tolerance. CD4+CD25+FOXP3+ regulatory T cells (Treg) are required for tolerance and function as dominant suppressors of innate and adaptive immune effector cells. In our prior phase 1 cGVHD study daily subcutaneous (SC) low-dose interleukin-2 (IL-2) for 8 weeks induced Treg expansion in vivo and objective clinical responses in 12 of 23 evaluable participants (NEJM 2011). We now report on a phase 2 trial of daily low-dose SC IL-2 at 1x106 IU/m2/d for 12 weeks in steroid-refractory cGVHD. The study comprised 35 HCT recipients (51% male, 91% HLA-matched PBSC grafts). Median participant age was 51 years (range, 22-72). Median time from HCT and from cGVHD onset to start of IL-2 treatment was 616 days (range, 270-2145) and 252 days (range, 28-1880) respectively. Participants had a median of 4 cGVHD organ sites (range, 1-7), and 2 concurrent cGVHD therapies (range, 1-3) at enrollment. The median baseline prednisone dose was 20 mg (range, 2.5-50). The median follow-up in survivors was 21 months (range, 4-35). 12 week low dose IL-2 was well tolerated: 2 participants withdrew and 5 required IL-2 dose reduction for constitutional AE (n=6) and thrombocytopenia (n=1); 1 had Gr 3 infection (bacteremia); and none experienced relapse. At week 12, objective cGVHD responses (PR) were documented in 21 of 33 evaluable participants (64%). Two (6%) had cGVHD progression. cGVHD response sites included skin (n=9), joint/fascia/muscle (n=4), liver (n=7), lung (n=3), and GI tract (n=4). Overall 2-year OS/PFS was 91% (responders 94%; non-responders 83%). 23 participants with clinical benefit (PR or SD with minor response) proceeded on extended IL-2 therapy. Immunologically, low dose IL-2 induced a >4-fold increase in median Treg count/µL (p<0.001): a rapid rise from a baseline of 17.1 (Q1-Q3, 8.6-40.6) to a week 4 peak of 137.9 (Q1-Q3, 51.8-188) and subsequent stabilization with a week 12 count of 104.1 (Q1-Q3, 53.9-167.1). No significant change in CD4 conventional T cell (Tcon), CD8 T cell, or CD20 B cell count was noted. NK cell count increased >3-fold (p<0.001). The median Treg:Tcon ratio increased >4-fold (p<0.001): a rapid rise from baseline of 0.06 (Q1-Q3, 0.05-0.13) to a week 2 peak of 0.35 (Q1-Q3, 0.26-0.48) that remained elevated through a week 12 ratio of 0.31 (Q1-Q3, 0.27-0.39) (Figure). Treg count and Treg:Tcon ratio declined during 4 weeks off IL-2 and rose thereafter on restarting IL-2. Clinical responders were younger (50 vs. 61.5 years, p=0.01) and initiated IL-2 earlier (499 vs. 903 days post HCT, p=0.015). Responders had a higher median Treg:Tcon ratio at study baseline (0.09 vs. 0.06, p=0.052) and at week 1 of IL-2 (0.3 vs. 0.14, p=0.01). Combining phase 1 and 2 data, Treg:Tcon ratios of ≥0.07 at baseline and ≥0.2 at week 1 of IL-2 were highly predictive of clinical response (p=0.007; p=0.0013 respectively). The combined phase 1 and 2 extended IL-2 cohort comprised 35 participants with a median follow up of 16.2 months (range, 4.1-66.8), with 20 and 12 participants receiving over 1 and 2 years of IL-2 respectively. Extended daily low dose IL-2 was well tolerated, and only 4 participants had Gr 3 AEs deemed IL-2 related: lung infection (n=1), arthralgia (n=1), and injection site induration (n=2). 5 participants required IL-2 dose reduction and 1 had hematologic malignancy relapse. Clinical responses were typically sustained during taper of concomitant immunosuppression. Treg augmentation persisted for the duration of IL-2 therapy. Tcon count slowly recovered to normal levels and Treg:Tcon ratio gradually normalized over a 2 year period. There was no change in CD8 count. The median steroid taper was 50% (range, -20-100). In summary, daily low dose IL-2 therapy induced profound Treg enhancement, and clinical responses in over half of refractory cGVHD patients. Early clinical response predictors suggest IL-2 is more effective earlier in the cGVHD course and when starting numbers of Treg are higher. Sustained clinical and immunologic response during extended IL-2 was documented. Long term tolerance induction with daily low dose IL-2 is a promising and feasible strategy. Optimizing IL-2 clinical response by further augmenting Treg and the Treg;Tcon ratio early in the course of cGVHD is worth exploring. Figure 1 Figure 1. Disclosures Koreth: Prometheus Laboratories Inc: Research Funding; Millennium Pharmaceuticals Inc: Research Funding; Takeda Pharmaceuticals Inc: Membership on an entity's Board of Directors or advisory committees. Off Label Use: Low-dose Interleukin-2 for immune tolerance. Chen:Bayer Pharmaceuticals, Inc.: Other, Research Funding. Avigan:Astex Pharmaceuticals : Research Funding.

Style APA, Harvard, Vancouver, ISO itp.

24

Hartshorn, MP, JM Readman, WT Robinson i J. Vaughan. "Nitration of 2,3,4,6-Tetramethylphenol and 1,2,3,5-Tetramethylbenzene". Australian Journal of Chemistry 38, nr 4 (1985): 587. http://dx.doi.org/10.1071/ch9850587.

Pełny tekst źródła

Streszczenie:

Nitration of 1,2,3,5-tetramethylbenzene (2a) with fuming nitric acid gives the tetramethylnitrobenzene (22), products of side-chain modification (23)-(27), the rearranged 6,6-dimethylcyclohexenones (8), (28), (29) and (30), and 2,3,4,6-tetramethyl ketone derivatives (10)- (13), (31) and (32). Reaction of 2,3,4,6-tetramethylphenol (7) with nitrogen dioxide gives the hydroxy dinitro ketone (9) in addition to the trinitrocyclohexenones (11)-(14) and (19). X-ray crystal structures are reported for compounds (11), (19), (28), (29), (30) and (32). 1H n.m.r ./stereochemistry correlations are reported for some 2,5-dinitro- and 2,5,6-trinitro-cyclohex-3-enones.

Style APA, Harvard, Vancouver, ISO itp.

25

Chittajallu, Vibhu, Arjun Chatterjee, Jaime Perez i Prabhleen Chahal. "619 10 YEAR OUTCOMES OF SMOKING CESSATION ATTEMPTS IN REDUCING LOW BONE DENSITY DISEASE IN CHRONIC PANCREATITIS". Gastroenterology 164, nr 6 (maj 2023): S—119. http://dx.doi.org/10.1016/s0016-5085(23)01248-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

26

Short, Scott S., Yosef Nasserl, Alexandra Gangi, Dror Berel i Phillip Fleshner. "Deep Vein Thrombosis Prophylaxis Increases Perioperative Surgical Site Infection in a Prospective Cohort of Patients Undergoing Colorectal Surgery". American Surgeon 77, nr 10 (październik 2011): 1309–13. http://dx.doi.org/10.1177/000313481107701007.

Pełny tekst źródła

Streszczenie:

We hypothesize that use of postoperative heparin deep vein thrombosis prophylaxis influences development of surgical site infection (SSI) after colorectal surgery. From July 2008 to June 2009, patients undergoing an abdominal operation by colorectal surgeons at a single university-affiliated teaching hospital were prospectively followed and more than 80 variables collected. One hundred eighty-one patients were identified. Forty-five per cent (n = 82) received heparin prophylaxis and 55 per cent (n = 99) did not. SSI occurred in 23 per cent (n = 19) of patients receiving heparin versus 9 per cent (n = 9) who did not ( P = 0.02). Univariate analysis found SSI to be associated with heparin ( P = 0.02) and increased operative time ( P = 0.03). Multivariate analysis showed that SSI was associated only with heparin use ( P = 0.04; OR, 2.6; 95% CI, 1.1 to 6.6).

Style APA, Harvard, Vancouver, ISO itp.

27

Galarza Fortuna, Gliceida, G. Daniel Grass, Benjamin L. Maughan, Rohit K. Jain, Christopher B. Dechet, Julia Beck, Ekkehard Schuetz i in. "NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma." Journal of Clinical Oncology 42, nr 4_suppl (1.02.2024): 612. http://dx.doi.org/10.1200/jco.2024.42.4_suppl.612.

Pełny tekst źródła

Streszczenie:

612 Background: Definitive chemoradiation (CRT) is the preferred bladder preservation treatment for non-metastatic urothelial cancer (nmUC). The NEXT trial (NCT03171025) evaluated the efficacy of adjuvant nivolumab to definitive CRT in pts with nmUC. Methods: This multicenter study enrolled nmUC pts who received standard-of-care CRT. Nivolumab 480 mg was administered every 4 weeks for up to 12 doses. Primary endpoint: failure-free survival (FFS) at 2 years (yrs). Secondary endpoint: safety. This is the first efficacy and safety analysis after completion of enrollment, and correlation of disease risk features, and changes in plasma cell-free DNA (cfDNA) with outcomes. Shallow whole genome sequenced data from plasma cfDNA was mapped to the human reference genome (HG19), and copy number instability (CNI) Score (Oncocyte) was derived from statistically significant altered regions. Results: From 8/03/2017 to 1/25/2023, 28 pts were enrolled. The median age was 72 yrs (range 54-86 yrs). Ten patients (36%) had ≥ T3 and/or N+ disease. At time of data cut-off (9/14/23), median nivolumab cycles were 8.5 (range 1-12), and median follow-up was 11 months (range 6 - 45). FFS at 2 yrs (n=24) was 38.7 % (95% CI 23%-65.2%). Disease relapse occurred in 16 pts, of which 9 had local recurrences. Grade ≥3 treatment-related adverse events (AEs) occurred at a frequency of 10.7%. These were elevated transaminases, diarrhea, and polymyalgia rheumatica. Grade 3 radiation therapy oncology group (RTOG) AEs occurred in 2 pts. One or more high-risk disease features (ie. plasmacytoid differentiation, T4, N+, multiple tumors, tumors > 5 cm, residual disease before CRT, CIS, and hydronephrosis) were present in 22 pts (79%). In a Cox proportional hazards model, the number of high-risk features was a significant predictor of progression (p = 0.006). Each additional high-risk feature was associated with a hazard ratio for progression of 1.77 (95% CI 1.17-2.67). Median CNI (mCNI) on C1D1 of nivolumab in relapsed pts was 31 (range 3-232) vs. 24 (range 3-109) in pts with ongoing response. The mCNI on C4D1 for pts who progressed was 15.5 (range 6-371) vs. 9 (range 3-65) in pts with ongoing response. Oncogenic gene copy number changes and the associated pathways associated with progression are listed in the table. Conclusions: Adjuvant nivolumab to CRT for nmUC has promising efficacy with tolerable AEs, even in pts with high-risk disease. Disease relapse correlates with high-risk clinical features and CNI in plasma cfDNA. Oncogenic copy number changes in genes involved in DNA repair, RTK-RAS-PI3K, WNT, and cell cycle pathways are present in cfDNA of those who progressed (Table). Clinical trial information: NCT03171025 . [Table: see text]

Style APA, Harvard, Vancouver, ISO itp.

28

Pan, Yi-Ru, Pang Hsiao, Chen-Yu Chang, Wen-Jong Ma, Hsiang Hsiao, Pei-Jung Lin, Shih-Chieh Wang, Hui-Jie Yang, Ting-Ting Chi i Chin-Kun Hu. "Universality and scaling in complex networks from periods of Chinese history". Chaos: An Interdisciplinary Journal of Nonlinear Science 33, nr 1 (styczeń 2023): 011101. http://dx.doi.org/10.1063/5.0134923.

Pełny tekst źródła

Streszczenie:

Critical physical systems with large numbers of molecules can show universal and scaling behaviors. It is of interest to know whether human societies with large numbers of people can show the same behaviors. Here, we use network theory to analyze Chinese history in periods 209 BCE–23 CE and 515–618 CE) related to the Western Han–Xin Dynasty and the late Northern Wei–Sui Dynasty, respectively. Two persons are connected when they appear in the same historical event. We find that the historical networks from two periods separated about 500 years have interesting universal and scaling behaviors, and they are small-world networks; their average cluster coefficients as a function of degree are similar to the network of movie stars. In the historical networks, the persons with larger degrees prefer to connect with persons with a small degree; however, in the network of movie stars, the persons with larger degrees prefer to connect with persons with large degrees. We also find an interesting similar mechanism for the decline or collapse of historical Chinese dynasties. The collapses of the Xin dynasty (9–23 CE) and the Sui dynasty (581–618 CE) were initiated from their arrogant attitude toward neighboring states.

Style APA, Harvard, Vancouver, ISO itp.

29

Sathi, Zakia Sultana, Ranjan Kumar Barman, M. Anwarul Islam, Md Mokhlesur Rahman i Md Anwar Habib. "Toxicological studies of a metabolite of Streptomyces species on Brine shrimp and Mice". TAJ: Journal of Teachers Association 23, nr 1 (1.06.2010): 6–9. http://dx.doi.org/10.3329/taj.v23i1.41122.

Pełny tekst źródła

Streszczenie:

The cytotoxic activity of the crude chloroform extract of Streptomyces species and a pure compound, 4-hydroxy nitrobenzene (ZS-3) isolated from chloroform extract was determined by brine shrimp lethality bioassay. The LD50 values of chloroform extract and compound (ZS-3) and ampicillin trihydrate were found to be 5.6, 6.6 and 5.0 μg ml-1, respectively. The acute toxicity of the compound (ZS-3) was also performed on Swiss albino mice. The median acute toxicity value (LD50) of ZS-3 was found to be 62 mg kg-1. Thus the isolated compound ZS-3 seems to be safe for therapeutic use. TAJ 2010; 23(1): 6-9

Style APA, Harvard, Vancouver, ISO itp.

30

Torres Valdiviezo, Lucero Itzel, Karla Lucero Rodríguez Flores, Vanessa Rosas Rosas Camargo, Alejandro Noguez-Ramos, Mónica Isabel Meneses Medina, Ximena Rosas Flota, Armando Gamboa Dominguez i Fidel David Huitzil Melendez. "Clinical characteristics, treatment, and oncological outcomes in patients with ampullary cancer at a reference center in Mexico." Journal of Clinical Oncology 40, nr 4_suppl (1.02.2022): 617. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.617.

Pełny tekst źródła

Streszczenie:

617 Background: Ampullary cancer (AC) represents 0.2% of gastrointestinal cancers. Given the rarity of the disease, information regarding treatment strategies and outcomes derives from studies that include the different types of periampullary cancers, which constitute a heterogeneous group. Our aim was to describe the clinical characteristics, treatment modalities and outcomes in patients (pts) with true AC treated at our institution. Methods: A retrospective review of medical records of all consecutive pts with histological diagnosis of AC evaluated at our institution from Jan 2009-Dec 2019. Clinical, pathological and laboratory variables at diagnosis were recorded. Overall survival (OS) was estimated by Kaplan-Meier and compared with the Log-rank test. Statistical significance was determined at P<0.05. Results: 133 pts with AC were included. Median age was 62 yo (IQR 53-70), 51.9% were women. 25% had ampullary adenoma history. Symptoms at diagnosis: 89% jaundice, 63% weight loss and 56% abdominal pain. Median laboratory values were total bilirubin 1.7 mg/dL (0.7-5.1), albumin 3.7 g/dL (3.1-4.2), hemoglobin 12.6 g/dL (10.9-14.2), carbohydrate antigen (CA) 19-9 34.7 U/mL (6.4-113.9) and carcinoembryonic antigen (CEA) 2.6 ng/mL (1.2-4.2). Most tumors were moderately differentiated (59%). Histologic subtypes of adenocarcinoma were available in 84 pts: intestinal 46.4%, pancreaticobiliary 39.3% and mixed 14.3%. Stage at diagnosis was localized (46%), locally advanced N+ (29%) and advanced (25%). For those with localized/locally advanced disease, 91% (91/100) underwent surgical resection, 25.3% (23/91) received adjuvant chemotherapy (ChT), 69.6% (16/23) received single agent and 30.4% (7/23) duplet. Pts who received adjuvant Cht presented N+ in 69.6%, moderate differentiation in 73.9%, intestinal 47.8% and pancreaticobiliary subtype 43.5%. In advanced setting, 63.6% (21/33) received palliative Cht, 66.7% received a duplet regimen. Median OS was 32.8 (22.9-42.8) months (mos). Median OS according to stage was 152.1, 28.1 and 10.2 mos for localized, locally advanced, and advanced, respectively (P<0.001). OS univariate analysis is shown in table. Conclusions: Most of pts presented with localized/locally advanced disease, were eligible to surgical resection and had a better survival. For those with N+ disease it is required to evaluate the role of adjuvant Cht. In the advanced setting, Cht improves prognosis.[Table: see text]

Style APA, Harvard, Vancouver, ISO itp.

31

An, Y. K., N. Lindsay, N. Allan, E. Khoo, R. Fernandes, A. Amiss, H. Pham i in. "P663 Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn’s disease patients: results from the AURORA Study including ANZIBDC Cohort". Journal of Crohn's and Colitis 17, Supplement_1 (30.01.2023): i793—i794. http://dx.doi.org/10.1093/ecco-jcc/jjac190.0793.

Pełny tekst źródła

Streszczenie:

Abstract Background Ustekinumab (UST) is a monoclonal antibody targeting IL-12 and IL-23 through their shared p40 subunit. This study aimed to determine the clinical outcomes after UST treatment in Crohn’s disease (CD) patients in a real-world setting, and to investigate the association of clinical outcomes with IL-12, IL-23 and UST levels. Methods A multi-centre prospective observational cohort study of UST for moderate to severe CD was conducted. Patients were recruited from 19 Australian centres between Sep 2019 and Apr 2022. Clinical assessments were performed at baseline study visit (SV) 1 and post-induction (SV2). Patients were assessed every 6 months during maintenance therapy to 18 months (SV4). Clinical response and remission rates were determined using PRO2 definitions (STRIDE II guidelines). Logistic regression analyses were performed to identify predictors of clinical response and remission. UST levels were measured post induction and interleukin levels including IL12p40 and IL-23p19 were measured at SV1 and SV2 using ProQuantum ELISA assays. Results A total of 198 patients were recruited: median age 40.7 years, 54.3% male, median duration of disease 90.5 months, 12.8% active smokers, and 49.7% on concomitant immunomodulatory therapy. The majority (58.4%) were biologic-naïve and 82 patients were previously exposed to biologics (51.9%; IFX n=42, ADA n=50, VDZ n=9). Clinical response was achieved in 137 patients (75.7%), and remission in 84 (46.4%) with higher rates of response (85.2% vs 61.6%, p=0.001) and remission (54.6% vs 34.2%, p=0.006) in biologic naïve patients compared to biologic-exposed. For the 114 patients with 18 months (SV4) of follow-up, durable clinical response was maintained in 66.8% and remission in 50.0%. Dose escalation (90mg 4 weekly) was administered to 13 patients (6.6%) during induction, 48 (42.1%) in maintenance, and 15 patients (13.2%) received IV re-induction during maintenance. There was a significant reduction in IL-12 and IL-23 levels from SV1 to SV2 in responders (p=0.0001), but no significant reduction in non-responders (Figure 1). Clinical response at SV4 (n=101) was associated with higher post-induction UST levels (p=0.03) (Table 1). The combination of IL-12. IL-23 and UST level at SV2 predicted long-term response at SV4 (Sn 73%, Sp 71%, AUROC 0.765), but not at SV2 (Figure 2). Conclusion This large real-world study confirms that UST is most effective in bio-naïve CD patients with significantly higher response and remission rates than bio-experienced patients. The combination of post-induction IL-12, IL-23, and UST levels was associated with response at 18 months and could represent a novel predictor of long-term clinical outcomes.

Style APA, Harvard, Vancouver, ISO itp.

32

Le Roy, Florence, Eugénie Rigault, David Regnault, Nicole Hubert, Pascal Burtin, Antoine Hollebecque, David Malka, Valerie Boige i Michel Ducreux. "Oxaliplatin desensitization after hypersensitivity reaction: A single-center experience on more than 300 procedures." Journal of Clinical Oncology 36, nr 4_suppl (1.02.2018): 610. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.610.

Pełny tekst źródła

Streszczenie:

610 Background: Oxaliplatin is an essential drug in gastrointestinal oncology. Hypersensitivity reactions (HSR) occur frequently (incidence varying from 10% to 25%), leading to permanent treatment discontinuation. The present study aimed to report our experience of oxaliplatin desensitization in patients with history of HSR to oxaliplatin. Methods: We retrospectively reviewed all patients who received at least one infusion of oxaliplatin according to a desensitization protocol after prior history of HSR to oxaliplatin, from June 2011 until June 2017. HSRs were classified from NCI CTC-AE grade 1 (transient rash, fever < 38°C) to grade 4 (anaphylaxis). We applied in all cases a desensitization protocol in which the oxaliplatin infusion rate is gradually increased from 1mL/hr. to 150mL/hr., on an inpatient basis. Intravenous or hepatic arterial infusion was used depending on clinical setting. Results: Overall, 54 patients were included in this study, in whom HSR to oxaliplatin occurred after a median of 9 infusions (range, 1-31). The severity of HSRs was grade 1-2 in 33 patients (61%) and grade 3-4 in 21 patients (39%). A total of 305 oxaliplatin infusions according to a desensitization protocol were performed in these 54 patients (median, 5 infusions; range, 1-20). These infusions were by intravenous route in 42 patients (78%), by hepatic arterial route in 11 patients (18%), and both in 2 patients (4%). Infusions were well tolerated in 41 patients (76%), without new HSR. The remaining 13 patients (24%) experienced HSR recurrence (grade 2, 9 patients [69%]; grade 3, 4 patients [31%]). No anaphylaxis or oxaliplatin-related death occurred. In the 21 patients with a prior history of severe (grade 3-4) HSR, oxaliplatin desensitization procedure was effective and sustained in 16 patients (79%). Among 32 evaluable patients, 23 (72%) experienced disease control (14 partial responses, 9 stable diseases). Conclusions: Rechallenging Oxaliplatin desensitization procedure was successful in three out of four patients with prior history of HSR to oxaliplatin. Our retrospective study confirms that oxaliplatin desensitization is safe, and allows patients who developed HSR to continue an effective treatment.

Style APA, Harvard, Vancouver, ISO itp.

33

Palmquist, Nathan C., Ryan Anderson, Jared A. Kearns, Joonho Back, Emily Trageser, Stephen Gee, Steven P. Denbaars i Shuji Nakamura. "Long-Cavity M-Plane GaN-Based Vertical-Cavity Surface-Emitting Lasers with a Topside Monolithic Curved Mirror". Photonics 10, nr 6 (3.06.2023): 646. http://dx.doi.org/10.3390/photonics10060646.

Pełny tekst źródła

Streszczenie:

We report long-cavity (60.5 λ) GaN-based vertical-cavity surface-emitting lasers with a topside monolithic GaN concave mirror, a buried tunnel junction current aperture, and a bottomside nanoporous GaN distributed Bragg reflector. Under pulsed operation, a VCSEL with a 9 µm aperture had a threshold current density of 6.6 kA/cm2, a differential efficiency of 0.7%, and a maximum output power of 290 µW for a lasing mode at 411 nm and a divergence angle of 8.4°. Under CW operation, the threshold current density increased to 7.3 kA/cm2, the differential efficiency decreased to 0.4%, and a peak output power of 130 µW was reached at a current density of 23 kA/cm2.

Style APA, Harvard, Vancouver, ISO itp.

34

DEMIRBILEK, SERPIL KAHYA, i ÖZGE YILMAZ. "Identification and antimicrobial susceptibility of microbial agents of otitis externa in dogs". Medycyna Weterynaryjna 74, nr 10 (2022): 6136–2022. http://dx.doi.org/10.21521/mw.6136.

Pełny tekst źródła

Streszczenie:

In this study, a total of 277 unmedicated dogs with otitis externa were used. Overall, 413 agents were isolated from 277 ear swab samples; 52.7% of the cases were mono-infections (146 cases), and 37.1% of the cases were poly-infections (103 cases). In 10.1% (28) of the cases, neither bacteria nor yeasts were isolated. Coagulase-positive Staphylococcus spp. were the most frequently isolated bacteria and were found in 90 (21.8%) of the samples. Fifty-eight samples, (14%) were positive for Staphylococcus aureus, 51 (12.3%) for Pseudomonas aeruginosa, 27 (6.5%) for Proteus mirabilis, 27 (6.5%) for Malassezia pachydermatis, 21 (5%) for Corynebacterium spp., 21 (5%) for β-haemolytic Streptococcus spp., 15 (3.6%) for Staphylococcus pseudointermedius, 12 (2.9%) for Proteus spp., 12 (2.9%) for Escherichia coli, 9 (2.1%) for Acinetobacter calcoaceticus, 7 (1.6%) for Trichophyton mentagrophytes, 5 (1.2%) for Staphylococcus auricularis, and 46 (11.1%) for different bacteria and yeasts. A total of 14 different bacteria and yeasts were isolated and identified. Kirby-Bauer antibiotic susceptibility testing was carried out for 10 different antibiotics. The bacterial isolates were found to be resistant to amoxicillin-clavulanic acid (45%), gentamycin (28%), ampicillin/cloxacillin (69%), tobramycin (28%), amikacin (23%), enrofloxacin (47%), chloramphenicol (58%), doxycycline (65%), lincomycin/spectinomycin (58%) and polymyxin B (62%). In conclusion, it is important to test the antimicrobial sensitivity of aetiological agents of otitis externa before treatment so as to prevent the development of antibiotic resistance in bacteria and yeasts.

Style APA, Harvard, Vancouver, ISO itp.

35

Mader, Nicolai, Christina Schoeler, Niloufar Pezeshkpour, Konrad Klimek, Daniel Groener, Christian Happel, Nikolaos Tselis, Philipp Mandel, Frank Grünwald i Amir Sabet. "Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer". Cancers 15, nr 18 (17.09.2023): 4605. http://dx.doi.org/10.3390/cancers15184605.

Pełny tekst źródła

Streszczenie:

177Lu-PSMA-617 radioligand therapy (177Lu-PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) currently consists of 4–6 cycles of 6.0–7.4 GBq of 177Lu-PSMA-617 each every 6–8 weeks. While safety and efficacy could be demonstrated in larger prospective trials irrespective of the tumor burden at 177Lu-PSMA RLT initiation, increased renal absorbed doses due to a reduced tumor sink effect in early responding, oligometastatic mCRPC patients pose difficulties. Response-adapted, dose distributing, intermittent treatment with up to six cycles has not been routinely performed, due to concerns about the potential loss of disease control. Treatment was discontinued in 19 early-responding patients with oligometastatic tumor burden after two (IQR 2–3) cycles of 177Lu-PSMA-RLT and 6.5 ± 0.7 GBq per cycle and resumed upon 68Ga-PSMA-11-PET/CT-based progression (according to the PCWG3 criteria). Subsequent treatment breaks were imposed if a PSMA-based imaging response could be achieved. A total of five (IQR 3–6) cycles reaching a cumulative activity of 32 ± 11 GBq were applied. A routine blood work-up including blood counts and liver and renal function was measured throughout the 177Lu-PSMA-RLT and follow-up to grade toxicity according to CTCAE v5.0 criteria. Survival outcome was calculated based on the Kaplan–Meier method. In total, treatment-free periods of 9 (IQR 6–17) cumulative months and the application of 177Lu-PSMA-RLT cycles over 16 (IQR 9–22) months could be achieved. Fifteen (84%) patients responded to subsequent cycles after the first treatment break and in 7/19 (37%) patients, intermittent 177Lu-PSMA-RLT consisted of ≥2 treatment breaks. The median PFS was 27 months (95% CI: 23–31) and overall survival was 45 months (95% CI: 28–62). No grade ≥3 hematological or renal toxicities could be observed during the 45 ± 21 months of follow-up. The cumulative mean renal absorbed dose was 16.7 ± 8.3 Gy and 0.53 ± 0.21 Gy/GBq. Intermittent radioligand therapy with 177Lu-PSMA-617 is feasible in early-responding patients with oligometastatic disease. A late onset of progression after subsequent cycles and the absence of significant toxicity warrants further investigation of the concept of intermittent treatment in selected patients.

Style APA, Harvard, Vancouver, ISO itp.

36

Bauné, Emmanuel, E. Galand, B. Leduey, G. Liberati, G. Cumino, S. Caminada, A. Di Gianfrancesco i L. Cipolla. "Grades 92 and 23: Weldability Assessment and Long-Term Performances for Power Generation Applications". Materials Science Forum 580-582 (czerwiec 2008): 383–88. http://dx.doi.org/10.4028/www.scientific.net/msf.580-582.383.

Pełny tekst źródła

Streszczenie:

Increased efficiency and emission reduction in modern power plants lead to the use of new advanced materials with enhanced creep strength, with the objective to increase the steam parameters of power plants. With over ten years on market and wide experience related to its use, ASTM Grade 92 is becoming one of the most required materials when high service temperatures are reached (max. 610°C). Its composition, with 9%Cr and 1.5%W, gives rise to martensitic microstructures which offer very high creep strength and long term stability. The improved weldability and creep-strength between 500 and 580°C of the low alloy ASTM Grade 23, as well as a cost advantage over higher Cr materials in this temperature range, make it one of the possible candidates to meet the stringent requirements of modern power plants. Air Liquide Welding (ALW) has optimized and distributes a complete product family for the welding of Grades 23 and 92. TenarisDalmine (TD) focused on the development of Grade 23 tubes and pipes and is working on the development of Grade 92. A deep characterization work of the microstructural evolution and long term creep performances of these high temperature resistant materials was thus undertaken by ALW and TD, in collaboration with the Centro Sviluppo Materiali (CSM). The joint characterization program consisted in the assessment of welded joints creep properties. Welded joints were produced using the gas tungsten (GTAW), shielded metal (SMAW) and submerged arc welding (SAW) processes. Mechanical and creep properties of weldments were measured both in the as welded and post weld heat treated conditions and proper WPS’s were designed in a manner such that industrial production needs were satisfied. Short term creep resistance of cross weld specimens was measured to be within the base material acceptance criteria. Long term base material and cross weld creep performance evaluation are now in progress.

Style APA, Harvard, Vancouver, ISO itp.

37

Madico, Guillermo, Thomas C. Quinn, Anne Rompalo, Kelly T. McKee i Charlotte A. Gaydos. "Diagnosis of Trichomonas vaginalisInfection by PCR Using Vaginal Swab Samples". Journal of Clinical Microbiology 36, nr 11 (1998): 3205–10. http://dx.doi.org/10.1128/jcm.36.11.3205-3210.1998.

Pełny tekst źródła

Streszczenie:

Trichomonas vaginalis infection is the most prevalent nonviral sexually transmitted disease (STD) in the world. A PCR test using vaginal swab samples for the detection of T. vaginalis was developed to add T. vaginalis infection to the growing list of STDs that can be detected by DNA amplification techniques. A primer set, BTUB 9/2, was designed to target a well-conserved region in the beta-tubulin genes of T. vaginalis. All strains (15 of 15) of T. vaginalistested were successfully detected by PCR giving a single predicted product of 112 bp in gel electrophoresis. No such targeted product was amplified with DNA from Trichomonas tenax,Trichomonas gallinae, Chlamydia trachomatis, Neisseria gonorrhoeae, Giardia lamblia, Chilomastix sulcatus, Dientamoeba fragilis, and Entamoeba histolytica. An optimal analytical sensitivity of one T. vaginalis organism per PCR was achieved. Culture, performed with the Inpouch TV culture system, was examined daily with a light microscope to identify T. vaginalis. Twenty-three of 350 (6.6%) vaginal swab samples from women attending an army medical clinic were culture positive forT. vaginalis. Of these culture positive specimens, PCR detected 22 of 23 (96%) with primer set BTUB 9/2, and wet preparation detected only 12 of 23 (52%). Seventeen specimens were BTUB 9/2-PCR positive and culture negative. Ten of these discordant specimens were determined to be as true positive by PCR using primer sets TVA 5-1/6 and/or AP65 A/B, which target different regions in theT. vaginalis genome, and seven were determined to be false positive. The sensitivity of BTUB 9/2-PCR was 97% and the specificity was 98%. The sensitivities of culture and wet preparation were 70 and 36%, respectively. The diagnosis of T. vaginalis infection by PCR is a sensitive and specific method that could be incorporated into a joint strategy for the screening of multiple STDs by using molecular amplification methods.

Style APA, Harvard, Vancouver, ISO itp.

38

Calais, Jeremie, Jeannine Gartmann, Wesley R. Armstrong, Pan Thin, Kathleen Nguyen, Vincent Lok, Laura Gosa i in. "Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial." Journal of Clinical Oncology 38, nr 15_suppl (20.05.2020): 5549. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5549.

Pełny tekst źródła

Streszczenie:

5549 Background: This was an open-label randomized prospective bi-centric single-arm phase II clinical trial of 177Lu-PSMA-617 molecular radiotherapy in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC) conducted at University of California Los Angeles (USA) and Excel Diagnostics & Nuclear Oncology Center (Houston, TX, USA) (NCT03042312). The study was investigator-initiated under an investigational new drug approval protocol (IND#133661) with authorization of charging for investigational drug (cost-recovery, Title 21 CFR 312.8). We report here the post-hoc analysis of overall survival (OS) in a single-study site cohort (UCLA). Methods: Patients with progressive mCRPC (biochemical, radiographic, or clinical) after ≥1 novel androgen axis drug (NAAD), either chemotherapy (CTX) naïve or post-CTX, with sufficient bone marrow reserve, normal kidney function, and sufficient PSMA-target expression by PET were eligible. Patients received up to 4 cycles of 177Lu-PSMA-617 every 8±1 weeks and were randomized into 2 treatment activities groups (6.0 or 7.4 GBq). Efficacy was defined as serum PSA decline of ≥50% from baseline and served as primary endpoint (hypothesis: ≥40% of responders after 2 cycles). Results: 43 patients were randomized to the 6.0 GBq (n= 14) and 7.4 GBq (n=29) treatment arms. 11/43 (26%) were CTX naïve while 10/43 (23%), 12/43 (28%), 5/43 (12%) and 5/43 (12%) had received 1, 2, 3 or 4 CTX regimens. Median baseline PSA was 29.2 ng/ml (mean 228.8, range 0.5-2082.6). 21/43 (49%) completed 4 cycles of 177Lu-PSMA-617 whereas 4/43 (9%), 13/43 (30%) and 5/43 (12%) underwent 1, 2 and 3 cycles. PSA decline of ≥50% was observed in 11/43 of patients (26%) after 2 cycles and in 16/43 (37%) at any time (best PSA response). 9/43 (21%) had a PSA decline of ≥90% and 23/43 (53%) had any PSA decline (>0%). After a median follow-up of 19.5 months the median OS was 14.8, 15.7 and 13.5 months in the whole cohort, the 6.0 GBq and 7.4 GBq treatment arms, respectively (p=0.68). Patients showing a PSA decline of ≥50% after 2 cycles and at any time had a longer OS: median 20.1 months vs. 13.6 (p=0.091) and 20.1 vs. 11.6 (p=0.002), respectively. Conclusions: In this post-hoc analysis of a single-site cohort of 43 patients included in a prospective phase II trial the median OS after 177Lu-PSMA-617 molecular radiotherapy in patients with progressive mCRPC was 14.8 months. There was no difference of efficacy between the 6.0 GBq and 7.4 GBq treatment arms. Clinical trial information: NCT03042312 .

Style APA, Harvard, Vancouver, ISO itp.

39

Jagannath, Sundar, Akshay Kharat, Alex Fu, Stephen Huo, Monal Kohli, Shayna Adams, Emeka Umeh i Miran Foster. "POSTER: MM-613 Healthcare Resource Utilization and Costs Among Patients With Relapsed/Refractory Multiple Myeloma Treated With Chimeric Antigen Receptor-T (CAR-T) Cell Therapy". Clinical Lymphoma Myeloma and Leukemia 23 (wrzesień 2023): S223. http://dx.doi.org/10.1016/s2152-2650(23)00847-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

40

Hamid, Anis, Santosh Gupta, Shivakumar Keerthikumar, Anupama Pasam, Megan Crumbaker, Anthony M. Joshua, Ernest Lam i in. "Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial." Journal of Clinical Oncology 41, nr 16_suppl (1.06.2023): 5064. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064.

Pełny tekst źródła

Streszczenie:

5064 Background: LuPARP (NCT03874884) is evaluating the safety and efficacy of olaparib in combination with 177Lu-PSMA-617 in patients (pts) with mCRPC who have progressed on an androgen receptor pathway inhibitors and docetaxel. We aim to identify potential prognostic and predictive biomarkers from serial CTC profiling. Methods: Twenty-six pts with high PSMA expression on PSMA-PET received 7.4 GBq of 177Lu-PSMA-617 every 6 weeks (wk) together with an escalating dose-schedule of olaparib (50mg BD – 300mg BD, days 2 to 14 or days -4 to 14) for up to 6 cycles. For CTC analysis, 10 mls of blood was collected at baseline, 12-weekly for 48 wk, and thereafter every 24 wk and at disease progression. CK+, CD45-, and DAPI+ CTCs were enumerated from 3 mls of blood and immunoassayed for PSMA expression using the Epic Sciences platform. Correlations between total and PSMA+ CTC counts and PSA50 response (PSA reduction of ≥ 50%) were evaluated. Low pass whole genome sequencing (lpWGS) was performed on baseline and longitudinal CTC samples to identify copy number alterations. Results: At baseline, 23 of 26 pts (88%) had detectable CTCs (median 2.9 CTC/ml, range 0-30), and of these 23 pts, 17 (74%) had detectable PSMA+ CTCs (median 0.9 CTC/ml, range 0.3-27), indicating heterogeneity of PSMA expression in CTCs. The CTC positivity rates (% of cases ≥1 CTC) at week (w)12, w24, w36, w48 and at disease progression were 57%, 58%, 75%, 36% and 100%, and the PSMA positivity rates (% of cases ≥1 PSMA+ CTC) were 38%, 36%, 22%, 50% and 56%, respectively. Fifteen of 20 (75%) evaluable pts with paired baseline and w12 CTCs had a ≥50% decline in total CTC count, of which 9/15 (60%) pts also achieved a PSA50 response. Five of these 9 (56%) pts had 100% CTC clearance at w12. In terms of PSMA+ CTCs, 14/15 (93%) evaluable pts had ≥50% PSMA+ CTC decline with 13 pts (93%) achieving complete CTC clearance by w12. Six of the 13 pts with complete PSMA+ CTC clearance at w12 also achieved a PSA50 response. Beyond PSMA expression, genomic heterogeneity was evident in baseline and on-treatment CTCs, including recurrent loss of PTEN, TP53, BRCA2, ATM, and RB1, and gain of AR and MYC. lpWGS in 10 baseline samples identified 5 cases with BRCA2 loss and 5 cases with ATM loss. Two pts with BRCA2 loss and 3 pts with ATM loss had a PSA50 response by w12. Conclusions: We observed high rates of total and PSMA+ CTCs in PSMA-expressing mCRPC. Total and PSMA+ CTCs decline with combined olaparib and 177Lu-PSMA-617 treatment. Early declines in total and PSMA+ CTCs including 12w CTC clearance paralleled PSA responses. Notably, total and PSMA+ CTCs rise again in the setting of disease progression. Serial CTC profiling may assist in tracking response to 177Lu-PSMA-617 therapy. Clinical trial information: NCT03874884 .

Style APA, Harvard, Vancouver, ISO itp.

41

Oldham, Brian. "The Metalwork". Proceedings of the Prehistoric Society 51, S2 (1985): 27–31. http://dx.doi.org/10.1017/s0079497x00078233.

Pełny tekst źródła

Streszczenie:

The excavation produced a total of 23 metal artefacts; five of copper alloy and eighteen of iron. This material was recovered from two trenches only (B and E). 7 ne relationship of types to trenches is given in table 2.Copper alloy (fig, 9).1. Terret ring. Oval in form and of circular cross-section, with a low ridge-moulding around the outer edge of the loop. The loop tapers gradually from 7.2 mm diameter at the terminals to 6.2 mm opposite them. The terminals are circular (12.8 mm diameter) and have a shallow groove incised around them close to their inner faces. The attachment bar is parallel-sided and of rectangular section (6.6 mm x 4.5 mm). External dimensions: 54 mm x 47.2 mm; weight 41.6 gm.

Style APA, Harvard, Vancouver, ISO itp.

42

De Vita, Ferdinando, Michele Orditura, Alessio Fabozzi, Maria Maddalena Laterza, Jole Ventriglia, Beatrice Savastano, Guido Giordano i in. "Incidence and prognostic significance of HER2 overexpression in gastric cancer (GC): A monoinstitutional retrospective analysis." Journal of Clinical Oncology 32, nr 3_suppl (20.01.2014): 160. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.160.

Pełny tekst źródła

Streszczenie:

160 Background: HER2 overexpression in GC is reported in 20% of cases; it is considered a negative prognostic factor with a positive predictive value of response to trastuzumab. We reviewed our case records analyzing its clinical significance. Methods: We retrospectively collected the data for patients (pts.) with histologically confirmed GC and tumor specimens. Results: From June 2011 to December 2012 we analyzed HER2 status in 76 pts with metastatic GC. (M/F 50/26, median age 64 years, ECOG performance status 0/1/2 = 59/12/5, G1/G2/G3 = 6.6%/22.4%/71%). In 36.8% of pts. gastric body was the primary tumor site. HER-2 overexpression was observed in 13 pts (17.1%). HER2-positive group had the following characteristics: M/F = 10/3, median age 63 years; Lauren’s histotype: 75% intestinal and 25% diffuse; G1/G2/G3 = 15.4%/30.8%/53.8%; T3-T4 tumors and N+ disease were observed in 46.1% respectively; the primary tumor site was: proximal 38.4%, distal 61.6%. 46.1% of pts with metastatic disease received a first line CT with a median progression free survival (mPFS) of 5 months (range, 3-7) and a median overall survival (mOS) of 9 months (range, 3-23). In HER2-negative group, (N= 63, M/F = 40/23, median age 64 years), 92.1% of pts. Lauren’s histotype: 45.5% intestinal and 54.5% diffuse; G1/G2/G3 = 4.8%/20.6%/74.6%; metastatic disease: 55.5%. T3-T4 tumors were assessed in 65.1% of pts and N+ disease in 61.9%. The primary tumor location was: proximal 38.1%, distal 61.9%. 57.1% with advanced disease received a first line CT with a mPFS of 5.5 months (range, 2-30) and a mOS of 10 months (range, 2-67). No statistically significant differences for mPFS (p: 0.08) and mOS (p: 0.06) were observed between HER2 positive and HER2 negative metastatic patients. Conclusions: According to our experience, HER2 overexpression doesn’t seem to correlate with a worse prognosis. In particular, it is not correlated with a worse histology and higher stage at diagnosis. Furthermore, no differences in terms of mPFS and mOS were observed between HER2 positive and HER2 negative metastatic pts.

Style APA, Harvard, Vancouver, ISO itp.

43

Sukarjati, Pungky Slamet Wisnu Kusuma i Asti Rahayu. "FORMULASI NANOEMULGEL KOMBINASI EKSTRAK N-BUTANOL PEGAGAN, EKSTRAK N-BUTANOL LERAK DAN MINYAK BIJI MIMBA MENGGUNAKAN DESAIN FULL FACTORIAL". Medical Sains : Jurnal Ilmiah Kefarmasian 7, nr 4 (15.12.2022): 993–1004. http://dx.doi.org/10.37874/ms.v7i4.656.

Pełny tekst źródła

Streszczenie:

Gel spermisida yang mengandung bahan aktif nonoxynol-9 merupakan salah satu kontrasepsi non hormonal berbentuk gel yang banyak digunakan di kalangan masyarakat, namun, senyawa nonoxynol-9 dapat menyebabkan iritasi dan gatal-gatal pada vagina. Pada penelitian ini dibuat alternatif herbal spermisida dari tanaman pegagan, lerak dan mimba yang diformulasikan dalam sistem penghantaran nanoemulgel. Pada penelitian ini dilakukan optimasi dan formulasi nanoemulgel berbahan kombinasi dari ekstrak n-butanol Pegagan, ekstrak n-butanol Lerak dan minyak biji Mimba menggunakan model full factorial design (23). Pada penelitian ini didapatkan hasil bahwa ukuran partikel nanoemulgel memiliki rentang 477,5 ± 0,2 hingga 781,2 ± 0,6 nm. Daya sebar dari Nanoemulgel memiliki rentang 5,8 ± 0,2 sampai 6,6 ± 0,1 cm. Zeta Potensial dari nanoemulgel memiliki rentang -37,1 ± 0,7 sampai -37,1 ± 0,7 mV. Rentang pH yang dihasilkan adalah 5,9 ± 0,1 hingga 6,6 ± 0,1, viskositas yang dihasilkan adalah 768 ± 0,8 hingga 833 ± 0,8 cps.Variabel konsentrasi ekstrak n-butanol lerak dan interaksi antara ekstrak n-butanol pegagan dan minyak biji mimba berpengaruh signifikan terhadap respon ukuran partikel dilihat dari nilai p-value < 0,05 dengan nilai masing-masing p-value 0,04 dan 0,036. Pada respon zeta potential dan respon daya sebar, semua variabel konsentrasi ekstrak n-butanol lerak, ekstrak n-butanol pegagan, minyak biji mimba, interaksi ekstrak n-butanol lerak dan ekstrak n-butanol pegagan, interaksi antara ekstrak n-butanol pegagan dan minyak biji mimba dan interaksi ekstrak n-butanol lerak dan minyak biji mimba memiliki nilai p-value > 0,05, sehingga dapat disimpulkan tidak ada berpengaruh signifikan terhadap respon zeta potential dan daya sebar.

Style APA, Harvard, Vancouver, ISO itp.

44

Hull, Larry A. "Apple, Dilute Test of Acaricides, 1987". Insecticide and Acaricide Tests 13, nr 1 (1.01.1988): 22. http://dx.doi.org/10.1093/iat/13.1.22a.

Pełny tekst źródła

Streszczenie:

Abstract Plots consisted of single trees in a randomized block design with 2 replicates of'Golden Delicious' and 2 replicates of'Red Delicious,' both spur types planted to a spacing of 6.1 × 10.7 m. Experimental sprays were applied to run-off with a handgun from a truck-mounted John Bean sprayer equipped with a 35 gal/min pump. Approximately 5.0 gal of spray was applied per replicate tree. Spray dates were as follows: 9 Apr (ECO-3187 treatments), 22 Apr (Morestan and all ABG treatments), 11 May (ABG-6162, 1081 ml/100 gal), 5 Jun (all treatments but Morestan and ABG), 16 Jun (all treatments but ECO-3187), 19 Jun (ECO-3187 treatments only), 30 Jun (all treatments but ECO-3187), 13 Jul (all treatments but ECO- 3187 and Kelthane), and 23 Jul (all treatments but ECO-3187). Morestan was applied only on 22 Apr, Savey substituted thereafter. On 13 Jul, the rate of Savey was increased from 20.3 to 42.7 g/100 gal. On 23 Jul, Savey (42.7 g/100 gal) was added to the first two ABG-6162 treatments and Kelthane 4F (406 ml/100 gal was added to the last two ABG-6162 treatments. General sprays of fungicides (Benlate, Polyram, Manzate, Bayleton, Dithane M-45), insecticides (Lorsban, Phosphamidon, Guthion, Sevin, Pydrin), and calcium chloride were made at 1- to 2-wk intervals throughout the experiment with a Friend Airmaster sprayer at 50 gal/acre. Effectiveness of the materials on the mites was evaluated by making several counts on random samples of 25 leaves/tree, 100 leaves/ treatment. Mite population pressure was heavy throughout the summer. Russet ratings are based on 30 'Golden Delicious' apples/replicate, 60/treatment. Fruits were rated as 1 (no russeting), 2 (light russeting), 3 (moderate russeting), or 4 (severe russeting). Possible ranges were 30-60 (none to light), 60-90 (light to moderate), and 90-120 (moderate to severe).

Style APA, Harvard, Vancouver, ISO itp.

45

VanderVeer, Elysha, Steven J. T. Huang, Helene Bruyere, Charles Li, Khaled Ramadan, Diego Villa, David W. Scott i in. "CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys". Clinical Lymphoma Myeloma and Leukemia 23 (wrzesień 2023): S331. http://dx.doi.org/10.1016/s2152-2650(23)01119-9.

Pełny tekst źródła

Style APA, Harvard, Vancouver, ISO itp.

46

Munjal, Deepika, i Poonam Choudhary. "MANAGEMENT OF INFERTILITY DUE TO ADENOMYOSIS AND OVARIAN ENDOMETRIOMA (MAMSADUSHTIJANYA GARBHASHYA VIKARA) BY AYURVEDIC REGIME: A CASE REPORT". International Journal of Research in Ayurveda and Pharmacy 15, nr 1 (29.02.2024): 1–4. http://dx.doi.org/10.7897/2277-4343.1511.

Pełny tekst źródła

Streszczenie:

Adenomyosis, also known as endometriosis interna, has been associated with multiparity, but currently, adenomyosis is diagnosed with increasing frequency in infertile patients since women delay their first pregnancy until their late 30s or early 40s. The prevalence of adenomyosis is 9% in healthy individuals, but in the case of those who have endometriosis, the prevalence is 70%. Ovarian endometrioma is the most common form of endometriosis; although most endometriomas are benign, some may undergo malignant changes. Here is a case study of a 30-years-old female patient residing in Jaipur who consulted in OPD of the National Institute of Ayurveda (NIA) Jaipur on 23-3-22 with the chief complaint of being unable to conceive for 4 years and associated complaint of pain in lower abdomen during menses in the last 3 years. Her sonography findings were suggestive of endometriosis stage-4 with adenomyosis and left ovarian endometrioma (6.6 cm). The patient was treated with yoga basti (Anuvasana basti with Triphaladi taila and aasthapana basti with lekhaniya mahakashaya) for 5 cycles, uttara basti with Apamarga kshara taila for 3 cycles and Rasanadi ksheerpaka. The patient missed her period on 8-1-23 and did her urine pregnancy test on 13-1-23, which was found to be positive. From this case study, it is concluded that yoga basti with lekhaniya mahakashya and Triphaladi Taila and uttara basti with Apamarga kshara taila are effective in treating infertility due to adenomyosis (Mamsadushti janya garbhashaya vikara).

Style APA, Harvard, Vancouver, ISO itp.

47

Giuliano, Dominic, i Marion McGregor DC. "No difference in learning retention in manikin-based simulation based on role". Journal of Chiropractic Education 30, nr 1 (1.03.2016): 20–24. http://dx.doi.org/10.7899/jce-15-1.

Pełny tekst źródła

Streszczenie:

Objective: We evaluated learning retention in interns exposed to simulation. It was hypothesized that learning would degrade after 6 months and there would be a difference in retention between interns who played a critical role versus those who did not. Methods: A total of 23 groups of 5 to 9 interns underwent a cardiac scenario twice during 1 simulation experience and again 6 months later. We captured 69 recordings (23 before debrief at baseline [PrDV], 23 after debrief at baseline [PoDV], and 23 at 6-month follow-up [FUV]). Students were assigned different roles, including the critical role of “doctor” in a blinded, haphazard fashion. At 6-month follow-up, 12 interns who played the role of doctor initially were assigned that role again, while 11 interns who played noncritical roles initially were newly assigned to doctor. All videos of intern performance were scored independently and in a blinded fashion, by 3 judges using a 15-item check list. Results: Repeated-measures analysis of variance for interns completing all 3 time points indicated a significant difference between time points (F2,22 = 112, p = .00). Contrasts showed a statistically significant difference between PrDV and PoDV (p = .00), and PrDV and FUV (p = .00), but no difference between PoDV and FUV (p = .98). This was consistent with results including all data points. Checklist scores were more than double for PoDV recordings (16) and FUV (15), compared to PrDV recordings (6.6). Follow-up scores comparing old to new doctors showed no statistically significant difference (15.4 vs 15.2 respectively, t21 = 0.26, p = .80, d = .11). Conclusions: Learning retention was maintained regardless of role.

Style APA, Harvard, Vancouver, ISO itp.

48

Beckmann, U., I. Baldwin, G. K. Hart i W. B. Runciman. "The Australian Incident Monitoring Study in Intensive Care: AIMS-ICU. An Analysis of the First Year of Reporting". Anaesthesia and Intensive Care 24, nr 3 (czerwiec 1996): 320–29. http://dx.doi.org/10.1177/0310057x9602400304.

Pełny tekst źródła

Streszczenie:

The AIMS-ICU project is a national study set up to develop, introduce and evaluate an anonymous voluntary incident reporting system for intensive care. ICU staff members reported events which could have reduced, or did reduce, the safety margin for the patient. Seven ICUs contributed 536 reports, which identified 610 incidents involving the airway (20%), procedures (23%), drugs (28%), patient environment (21%), and ICU management (9%). Incidents were detected most frequently by rechecking the patient or the equipment, or by prior experience. No ill effects or only minor ones were experienced by most patients (short-term 76%, long-term 92%) as a result of the incident. Multiple contributing factors were identified, 33% system-based and 66% human factor-based. Incident monitoring promises to be a useful technique for improving patient safety in the ICU, when sufficient data have been collected to allow analysis of sets of incidents in defined “clinical situations”.

Style APA, Harvard, Vancouver, ISO itp.

49

Bragg, D. E., i D. Mayer. "Flea Beetle Control in Canola, 1994B". Arthropod Management Tests 20, nr 1 (1.01.1995): 155. http://dx.doi.org/10.1093/amt/20.1.155a.

Pełny tekst źródła

Streszczenie:

Abstract Plots were planted 6 May near Pomeroy, WA, at a rate of 6 lb/acre in rows 7 inches apart. Plots were 20 × 2 ft, replicated in a RCBD 4 times, and were situated with replicates perpendicular to a grass field. Precounts (PrCt) of plant stand per 6.6 ft row, and damage on 20 randomly selected plants on a scale of 0 to 6, with 0 = no damage and 6 = total destruction, were made 22 May. Five insecticide treatments were applied with a CO2 backpack sprayer at 20 gpa and 20 psi on 23 May. Conditions at treatment were 80 F° with no wind at 4 pm. Plants were in the first leaf stage. Evaluations of stand reduction and plant damage were made on 2, 5, 7 and 10 DAT. All surviving plants were in the 7 to 9 leaf rosette stage on 10-DAT.

Style APA, Harvard, Vancouver, ISO itp.

50

Sartor, Catherine, Christine Zandotti, Fanny Romain, Véronique Jacomo, Sophie Simon, Catherine Atlan-Gepner, Roland Sambuc, Bernard Vialettes i Michel Drancourt. "Disruption of Services in an Internal Medicine Unit Due to a Nosocomial Influenza Outbreak". Infection Control & Hospital Epidemiology 23, nr 10 (październik 2002): 615–19. http://dx.doi.org/10.1086/501981.

Pełny tekst źródła

Streszczenie:

Objective:To describe a nosocomial influenza A out-break, how it was managed, what impact it had on subsequent delivery of health care, and the additional charges attributable to it.Design:Prospective cohort study and microbiological investigation.Setting:One internal medicine unit in an acute care, university-affiliated hospital.Participants:Twenty-three patients and 22 staff members from February 28 to March 6,1999.Results:Attack rates were 41% (9 of 22) among patients and 23% (5 of 22) among staff members, with 3 of 14 cases being classified as “certain”. The influenza virus isolates were typed as A/SYDNEY/5/97 (H3N2). The index case was a patient who shared a room with the first nosocomial case. Vaccination rates for influenza virus were 43% (10 of 23) among patients and 36% (8 of 22) among staff members. The outbreak resulted in staff members' taking 14 person-days of sick leave. Furthermore, 8 scheduled admissions were postponed and all emergency admissions were suspended for 11 days. Hospital charges attributable to the influenza outbreak totaled $34,179 and the average extra charge per infected patient was $3,798.Conclusions:Nosocomial influenza outbreaks increase charges and alter the quality of care delivered in acute care settings. Strategies for their prevention need to be evaluated in acute care settings. (Infect Control Hosp Epidemiol 2002;23:615-619).

Style APA, Harvard, Vancouver, ISO itp.

Artykuły w czasopismach na temat „616.9 23”

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych